Drug, bio-affecting and body treating compositions inventions 11/08

20080293617 - Implantable putty material: The present invention provides compositions for an implantable putty material for delivery of active compounds to a patient. More specifically, the present invention provides a material having a pH of between about 3 and 6 and possessing putty-like physical properties, wherein the composition of the material includes collagen and water.... Agent: Williams, Morgan & Amerson

20080293618 - Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors: e

20080293619 - Compositions and methods for treating malaria with cupredoxin and cytochrome: The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by P. falciparum. The invention provides isolated... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080293623 - Enriched haptoglobin polymers for the treatment of disease: Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both... Agent: Knobbe Martens Olson & Bear LLP

20080293620 - Immunogenic glycopeptides for diagnosing pathogenic microorganisms infections: A method for diagnosing an infection in a patient likely to be infected with a pathogenic microorganism, comprising the detection of CD4+ T lymphocytes recognizing at least one glycopeptide derived from said pathogenic microorganism, essentially consisting of a glycosylated T epitope, comprising from 14 to 25 amino acids, among which... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080293621 - Methods for prolonging feline life: Methods for prolonging feline life by maintaining a feline on a food having reduced levels of protein, phosphorus, and sodium when compared to a standard feline maintenance food.... Agent: Colgate-palmolive Company

20080293622 - Methods of inducing ovulation: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's... Agent: Howrey LLP - Dc

20080293629 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080293638 - Albumin-fused ciliary neurotrophic factor: The invention relates to a fusion protein comprising an albumin, or a fragment or a variant or a derivative thereof and at least one biologically active peptide which activates the ciliary neurotrophic factor (CNTF) receptor, or a fragment or variant or a derivative thereof.... Agent: Fox Rothschild LLP

20080293635 - Angiogenic composition: e

20080293634 - C-met receptor regulation by angiotensin iv (at4) receptor ligands: The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or... Agent: Seed Intellectual Property Law Group PLLC

20080293637 - Cross-linked collagen and uses thereof: The present invention discloses collagen cross-linked in a micro to non-fibrillar form and at a high concentration. The cross-linked collagen gel has improved volume stability or persistence than collagen cross-linked at a neutral pH. Also disclosed are methods for preparing the inventive cross-linked collagen and using such for augmenting soft... Agent: Allergan, Inc.

20080293625 - Diagnosis of inflammatory bowel diseases, more particularly ulcerative colitis: The present invention concerns goblet cell antigen, a method for detecting antibodies directed against goblet cell antigen, a method based thereon for diagnosis of inflammatory bowel diseases and a kit for diagnosis of inflammatory bowel diseases, as well as monoclonal antibodies directed against goblet cell antigen.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080293628 - Methods and compositions for the inhibition of thrombus formation: The present invention is directed to anti-platelet peptides that may be used in various methods for the treatment or prophylaxis of thrombosis. More specifically, the specification describes methods and compositions for making and using compositions GPIbα fragments as anti-platelet agents. The present invention is also directed to peptides that inhibit... Agent: Marshall, Gerstein & Borun LLP

20080293630 - Mucoadhesive pharmaceutical compositions comprising chemoattractants: The invention relates to a mucoadhesive pharmaceutical composition comprising a polymer and a chemoattractant wherein the pH of the composition is greater than 6 which is useful in the treatment of a anogenital or oral disease, particularly an anogenital or oral disease cause by the human papillomavirus.... Agent: Jacobson Holman PLLC

20080293633 - Pharmaceutical formulations, methods, and dosing regimens for the treatment and prevention of acute coronary syndromes: The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano: phospholipid complex to reduce and stabilize atherosclerotic plaque. Pharmaceutical formulations of the Apo A-I Milano:phospholipid complexes are also provided.... Agent: Pfizer Inc.

20080293626 - Pigment epithelium-derived factor as a therapeutic agent for vascular leakage: The present invention relates to method of treating a patient with a condition involving increased vascular permeability or increased angiogenesis comprising administering to the patient a therapeutically effective amount of PEDF, PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide, a homolog of the PEDF 44 AA... Agent: Edwards Angell Palmer & Dodge LLP

20080293636 - Protein constructs designed for targeting and lysis of cells: The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a... Agent: Occhiuti Rohlicek & Tsao, LLP

20080293624 - Stabilized fgf formulations containing reducing agents: Stabilized FGF compositions are provided. The compositions comprise FGF or variant thereof and at least one reducing agent in an amount sufficient to inhibit FGF oxidation. Methods for increasing stability of FGF or variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition... Agent: Alston & Bird LLP

20080293627 - Thyrotropin receptor preparations, binding regions thereof, antibody and hormone interactions therewith, and uses thereof: A mutated TSHR preparation which includes at least one point mutation characterised in that at least amino acid Arg at a position corresponding to amino acid 255 of a full length human TSHR has been mutated to a different amino acid residue in said mutated TSHR preparation, whereby said mutated... Agent: Stites & Harbison PLLC

20080293631 - Treatment for autoimmune and inflammatory conditions: The present invention provides methods for preventing the elevation of blood glucose levels, for preventing or delaying the onset of autoimmune and inflammatory diseases or glucose-associated conditions, and for preventing or reducing inflammation in individuals suffering from an autoimmune or inflammatory diseases, the methods comprising administering to subjects in need... Agent: Clark & Elbing LLP

20080293632 - Use of natriuretic peptides for the treatment of stature disorders related to shox gene: The invention relates to the use of natriuretic peptides (ANP or BNP) for the preparation of pharmaceutical compositions for the treatment of short stature in a subject being suspected of having a genetic defect in the human SHOX gene. Further, the invention relates to use of natriuretic peptides in combination... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080293639 - Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable... Agent: Beyer Weaver LLP

20080293641 - Biologically active peptides: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.... Agent: EagleIPLimited

20080293640 - Polypeptide inhibitors of hsp27 kinase and uses therefor: The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080293642 - C-glycosylisoflavones having alkylaminoalkoxyl substituent, preparation and use of the same: The present invention relates to C-Glycosylisoflavones having alkylaminoalkoxyl substituent and pharmaceutically acceptable salts thereof, a process for the preparation thereof, pharmaceutical compositions comprising an effective amount of a compound of the formula (I), and to the use of these compounds or compositions for the treatment or prevention of cardio- and... Agent: Christie, Parker & Hale, LLP

20080293643 - Crystalline form i of 3,4'5-trihydroxy-stilbene-3-b-d glucoside: The present invention relates to a novel crystalline form of a Compound 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside (polydatin) and a method of preparation and use thereof, and to a pharmaceutical composition containing crystalline form I of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside. Crystalline form I of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside of the present invention has a stable crystalline morphology, a definite melting... Agent: Scully Scott Murphy & Presser, PC

20080293644 - Guava extract: The invention describes the preparation, isolation and use of an extract of guava fruit for the treatment of a disease or condition related with, caused by or mediated by dipeptidyl peptidase IV.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080293645 - Antiparasitic combination and method for treating domestic animals: This invention relates an antiparasitic combination for conveniently treating multiple types of parasites in domestic animals. Specifically, this invention provides a convenient combination and a method for removing worms from a gastrointestinal tract of a domestic animal while also preventing heartworm. The antiparasitic combination for the treatment of domestic animals... Agent: Pauley Petersen & Erickson

20080293646 - Macrolides: i

20080293647 - Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer: There is provided according to the invention a method of treating a patient with bladder cancer by administering a effective amount of a vitamin D compound in combination with one or more other antiproliferative agents. Also provided are uses of a vitamin D compound in combination with one or more... Agent: Edwards Angell Palmer & Dodge LLP

20080293648 - Compositions and methods for cancer treatment: This invention provides methods, novel formulations and kits to reduce the toxicity of anticancer drugs. Disclosed are therapeutics and treatment methods employing anticancer drags that exhibit a known toxicity, including, for example, adriamycin, campthothecin, and the like, chemically linked to a phosphonoformic acid partial ester resulting in a novel formulation... Agent: Williams Mullen

20080293649 - Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.... Agent: Seed Intellectual Property Law Group PLLC

20080293651 - Cytosine nucleoside analogs and isoflavones and uses thereof: Methods, uses, compositions and kits relating to the inhibition and/or prevention of undesirable cell proliferation, and prevention and/or treatment of diseases or disorders associated with such proliferation, such as cancer, using a cytosine nucleoside analog and an isoflavone, are described.... Agent: Darby & Darby P.C.

20080293650 - Fused heterocyclic compounds and use thereof: t

20080293658 - Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells: A pharmaceutical composition that blocks angiogenesis comprising as active agent at least one substance selected from the group consisting of (i) a nucleic acid molecule of a gene coding for protein IRS-1, a complementary sequence or a fragment thereof and (ii) a molecule which inhibits expression of a nucleic acid... Agent: Ip Group Of Dla Piper US LLP

20080293663 - Cellular genes regulated by hiv-1 infection and methods of use thereof: This invention provides cellular gene products which have anti-apoptotic activity in HIV-1 infected cells and provides agents for the inhibition of the cellular gene products.... Agent: Dann, Dorfman, Herrell & Skillman

20080293660 - Chemically-defined non-polymeric valency platform molecules and conjugates thereof: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies.... Agent: Morrison & Foerster LLP

20080293652 - Combination of ad-p53 and chemotherapy for the treatment of tumours: The present invention relates to the use of p53 gene therapy to treat recurrent cancers in combination with a radio- or chemotherapy. Patients with recurring cancers are treated with a p53 expression construct followed by subsequent radio- or chemotherapy treatment. Viral and non-viral delivery systems, as well as various radio-... Agent: Fulbright & Jaworski L.L.P.

20080293659 - Fc gamma riia-specific nucleic acid interference: The present invention provides methods and compositions for attenuating expression of FcγRIIA. In general, the described methodology involves the use of RNAi constructs that are targeted to a FcγRIIA mRNA sequence.... Agent: Wolf Greenfield & Sacks, P.C.

20080293661 - Method for treating chronic lymphoid leukemia: Embodiments of the invention relates to the treatment of chronic lymphoid leukemia. The invention provides treatment, diagnostic, and drug discovery strategies for chronic lymphoid leukemia. Reconstitution of RhoH expression in vitro inhibits neoplastic proliferation and the process of trans-endothelial migration that underlies much of the pathology of CCL. RhoH reconstitution... Agent: David S. Resnick

20080293653 - Method of treating autoimmune diseases: The invention features a method of inducing an apoptosis-resistant cell to undergo apoptosis, in which the cell is associated with an autoimmune disease such as multiple sclerosis. The method involves sensitizing the cell to apoptosis stimuli by treating the cell with an IAP antisense oligonucleotide, so that the cell undergoes... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20080293657 - Modulation of the expression of stat-1-dependent genes: The present invention relates to decoy-oligonucleotides and antisense-oligonucleotides having the nucleic acid sequence according to SEQ ID NO: 1 to 43 as well as the use thereof as medicaments.... Agent: Fulbright & Jaworski L.L.P.

20080293655 - Novel tandem sirnas: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of two or more target genes.... Agent: Cooper & Dunham, LLP

20080293656 - Processing nucleic acid: e

20080293662 - Rnai modulation of the bcr-abl fusion gene and uses thereof: The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.... Agent: Lowrie, Lando & Anastasi, LLP A2038

20080293654 - Therapeutic methods using smads: Methods of inducing the expression of a Smad in a cell or tissue comprising the step of contacting the cell or tissue capable of expressing the Smad with a bone morphogenic protein are provided. Methods of inducing tissue formation and repairing a tissue defect or regenerating tissue, at a target... Agent: Ropes & Gray LLP

20080293664 - Non-nucleoside reverse transcriptase inhibitors: Compounds of formula I, wherein R1, R2, R3, R4, Ra, X, X1, and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080293666 - Antibacterial agents: The invention provides compounds of formula (I) and salts thereof: R1-L-R2—B wherein R1, L, R2, and B have any of the values defined herein, as well as compositions comprising such compounds, and therapeutic methods comprising the administration of such compounds or salts. The compounds block siderophore production in bacteria and... Agent: Viksnins Harris & Padys Pllp

20080293665 - Purine nucleotide derivatives: This invention provides novel 8-carbyl substituted Camps (adenosine 3′,5′-cyclic monophosphorothioate) and a novel procedures for the preparation of 8-Br-cAMP, a key starting material.... Agent: Sughrue Mion, PLLC

20080293667 - Lipid analogs for combating tumors: The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the activity of the viral infection.... Agent: Morgan Lewis & Bockius LLP

20080293668 - [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including... Agent: King & Spalding LLP

20080293669 - Composition containing beta-glucan, method of producing the same and foods, drinks or skin moisturizers containing the composition: It is intended to utilize β-glucan produced by a bacterium belonging to Aureobasidium sp. From a bacterium belonging to Aureobasidium sp., a mutant with little pigment accumulation is constructed by a mutagenesis means of, for example, irradiating with ultraviolet light or treating with a mutagen. A culture obtained by culturing... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080293670 - Edible tremella polysaccharide for prevention and/or improvement of intestinal disorder: It has been found that the polysaccharide isolated from a hot water extract of a Tremella mushroom without adding a chemical reagent has a novel effect of preventing and/or treating of intestinal disorder. The Tremella polysaccharide has excellent stability, water absorbing and holding ability, and swelling capacity, so it can... Agent: Bacon & Thomas, PLLC

20080293671 - Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia: The present invention relates to pharmaceutical compositions comprising a fibrate (e.g. ciprofibrate, gemfibrozil, benzafibrate, and fenofibrate) and a polychitosamine (e.g. chitosan) having molecular weights of less than 650 Kda and degrees of deacetylation of from 70% to 100%. Uses of said compositions for the treatment of hyperlipidemia and associated conditions... Agent: Choate, Hall & Stewart LLP

20080293672 - Lipid conjugates in the treatment of disease: The invention relates to methods of use for compounds in treating, reducing the incidence, reducing the severity or pathogenesis of an intestinal disease or condition in a subject, including, inter alia, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or a combination thereof.... Agent: Pearl Cohen Zedek Latzer, LLP

20080293673 - N-acetyglucosamine derivatives and use thereof: It is intended to provide an easily available hyaluronic acid production promoting agent and a skin external preparation whereby the production of hyaluronic acid can be promoted in the skin and thus the skin can be maintained in a vital and moist state so that it is expected that the... Agent: Foley And Lardner LLP Suite 500

20080293674 - Azinyl imidazoazine and azinyl carboxamide: whereby the symbols have the meanings given in the description, as well as to methods for their preparation and new intermediates. The invention further relates to the use of the compounds of structure (I) and the intermediates for the control of zoopests and undesirable micro-organisms.... Agent: Bayer Cropscience Lp

20080293676 - Insecticidal agents based on selected insecticides and safeners: e

20080293677 - Use of alternating amine and non-amine bisphosphonate combinations for treating osteoporosis: A method of treating osteoporosis in a human in need thereof by administering alternating amine and non-amine bisphosphonates in a defined dosing schedule. The invention demonstrates an effective response and sustained benefit in the treatment of osteoporosis. Particularly, the method involves administration of a time-dependent dose of more than one... Agent: Baker Botts L.L.P.

20080293678 - Organic nitric oxide donor salts of angiotensin converting enzyme inhibitors, compositions and methods of use: The invention describes compositions and kits comprising at least qrie organic nitric oxide enhancing salt of an angiotensin converting enzyme inhibitor, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases;... Agent: Wilmerhale/nitromed

20080293675 - Antibiotics containing borinic acid complexes and methods of use: The structure and preparation of antibiotics incorporating borinic acid complexes are disclosed, especially hydroxyquinoline, imidazole and picolinic acid derivatives, along with compositions of these antibiotics and methods of using the antibiotics and compositions as bactericidal and fungicidal agents as well as therapeutic agents for the treatment of diseases caused by... Agent: Morgan, Lewis & Bockius LLP (sf)

20080293679 - Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors: Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20080293680 - Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii: The invention relates to a compound of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080293681 - Sprayable pharmaceutical compositions comprising a vitamin d derivative and an oily phase: Anhydrous sprayable physically and chemically stable pharmaceutical/dermatological compositions containing a vitamin D derivative as an active pharmaceutical ingredient, particularly calcitriol, and an oily phase are formulated into a physiologically-acceptable medium, and are useful for the treatment of a variety of conditions and afflictions, notably psoriasis.... Agent: Buchanan, Ingersoll & Rooney PC

20080293682 - Novel betulinic acid derivatives: The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(═CH2) CH3 or CH(CH3)2; R2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; R3 or R4 are hydrogen or aryl with the proviso that both are... Agent: Ladas & Parry LLP

20080293683 - Hormone replacement therapy: A hormone replacement therapy formulation and method comprising selective estrogenic compounds which preferentially stimulate the estrogen receptor alpha over the estrogen receptor beta.... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20080293684 - Heterocyclic acetophenone potentiators of metabotropic glutamate receptors: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed... Agent: Merck And Co., Inc

20080293686 - Semi-solid systems containing azetidine derivatives: e

20080293685 - Spiro and other derivatives of diamondoids possessing therapeutic activity in the treatment of viral disorders: This invention relates to diamondoid derivatives which exhibit therapeutic activity. Specifically, the diamondoid derivatives herein exhibit therapeutic effects in the treatment of viral disorders. Also provided are methods of treatment, prevention and inhibition of viral disorders in a subject in need.... Agent: Crowell & Moring LLP Intellectual Property Group

20080293687 - Benzamide compounds: The invention concerns benzamide compounds of Formula (I), wherein R1a, R1b, R1c, R2, R3, R4, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent... Agent: Morgan Lewis & Bockius LLP

20080293688 - Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080293690 - [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists: e

20080293689 - Compounds with atypical antipsychotic activity:

20080293691 - Treatment method: The present invention is directed to methods of treating an ocular neovascular disorder in a mammal by administration of pyrimidine derivatives, benzodiazepinyl derivatives and pharmaceutical compositions containing the same. The invention encompasses methods of treating an ocular neovascular disorder by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080293692 - Succinoylamino lactams as inhibitors of a-beta protein production: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly,... Agent: Kelley Drye & Warren LLP

20080293694 - New compounds: i

20080293693 - Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist: Disclosed herein is a method for preventing ovarian hyperstimulation syndrome in a subject by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier. Also disclosed herein is a method for treating ovarian hyperstimulation syndrome by administering an effective amount of a dopamine agonist in a pharmaceutically... Agent: Darby & Darby P.C.

20080293695 - Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance: Drug substances comprising a pharmaceutically acceptable organic acid addition salt 6f amine containing pharmaceutically active compounds useful for the treatment of a therapeutic ailment administration and exhibiting prophylactic properties when employed in non-therapeutic administration.... Agent: Nexsen Pruet, LLC

20080293696 - 2-aminoarylcarboxamides useful as cancer chemotherapeutic agents: wherein the group R4 represents halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings,... Agent: Barbara A. Shimei Director, Patents & Licensing

20080293697 - Pyrazolo[4,3-d]pyrimidines: This invention relates to compounds of formula (I).... Agent: Pharmacia Corporation Global Patent Department

20080293699 - Inhibitors of thapsigargin-induced cell death: Methods for screening for inhibitors of endoplasmic reticulum (ER) stress are provided. These methods involve the addition of thapsigargin, which induces ER stress, and a test agent to mammalian cells in multi-well plates. Cell survival can be readily monitored by measuring intracellular ATP content using a bioluminescent reagent. Screening a... Agent: Biotechnology Law Group C/o Portfolioip

20080293698 - Methods and compositions for treating arg: The invention provides dilute and concentrated, aqueous, pharmaceutical compositions comprising gamma-hydroxybutyric acid or pharmaceutically acceptable salts thereof; gamma-butyryl lactone; 1,4-butanediol; 4-hydroxyl pentanoic acid or pharmaceutically acceptable salts thereof; 4-hydroxyl pentanoic acid lactone, or combinations thereof, and a coloring agent and/or flavoring agent that is useful in preventing sexual assault or... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080293700 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell... Agent: Casimir Jones, S.c.

20080293701 - 1-acylamino-2-hydroxy-3-amino- -arylalkanes as renin inhibitors: 1-Acylamino-2-hydroxy-3-amino-ω-arylalkanes of formula I. and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080293702 - Nitric oxide enhancing pyruvate compounds, compositions and methods of use: The invention provides novel compositions and kits comprising at least one nitric oxide enhancing pyruvate compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular... Agent: Wilmerhale/nitromed

20080293703 - Topical preparation and method for transdermal delivery and localization of therapeutic agents: Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering... Agent: Law Office Of Jay R. Yablon

20080293705 - A1 adenosine receptor antagonists: s

20080293704 - Factor xa inhibitors: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat certain... Agent: Foley & Lardner LLP

20080293706 - Quinoxaline derivatives as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Corporate Intellectual Property - Uw 2220

20080293707 - Use of kiralaxyl for protecting phytopathogens, and corresponding methods and compositions: The invention relates to a method for protecting against phytopathogens which comprises treating seed with kiralaxyl (methyl N-(phenylacetyl)-N-(2,6-xylyl)-D-alaninate) in combination with at least one further pesticide and furthermore to the corresponding use of kiralaxyl in combination with at least one further pesticide and to corresponding compositions. Also described is special... Agent: Birch Stewart Kolasch & Birch

20080293710 - Aerosol formulation for the inhalation of beta-agonists: e

20080293709 - Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20080293708 - Pyrimidine derivatives: i

20080293711 - Chemokine receptor modulators:

20080293712 - Benzo[c][2,7]naphtyridine derivatives, methods of making thereof and methods of use thereof: The present invention relates to Benzo[c][2,7]naphthyridine Derivatives, compositions comprising an effective amount of a Benzo[c][2,7]naphthyridine Derivative, methods for treating or preventing a proliferative disorder or an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a Benzo[c][2,7]naphthyridine Derivative, methods for modulating PDK-1 activity, PKA activity,... Agent: Wyeth Patent Law Group

20080293713 - Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme: e

20080293714 - Tec kinase inhibitors: Disclosed are compounds of formula (I): (F) wherein Ri, R2, X and Ar are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080293715 - Therapeutic pyrazolo[3,4-b]pyridines and indazoles: wherein R2, R3, R4, R5, R6, R7, X, and L have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of central nervous disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, anxiety, depression, and... Agent: Pharmacia Corporation Global Patent Department

20080293717 - Aryl sulfonamides: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080293716 - Chemical compounds: There is provided a compound of Formula (I) or a salt, solvate, or physiologically functional derivative thereof:... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080293718 - Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20080293719 - Pyridiazinone derivatives for the treatment of tumours: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours... Agent: Millen, White, Zelano & Branigan, P.C.

20080293721 - Arylthioacetamide carboxylate derivatives as fkbp inhibitors for the treatment of neurological diseases: wherein Z is selected from a group consisting of O, C, N, and S; each of Ar1, Ar2, and Ar3 is a moiety selected from a group consisting of an aryl and a substituted aryl; Y is selected from a group consisting of S, O, CH2 and SO2; K is... Agent: Dla Piper US LLP

20080293720 - Pyridinyl sulfonamide modulators of chemokine receptors: e

20080293722 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Wyeth Patent Law Group

20080293723 - Spiroindolinone derivatives: e

20080293724 - Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate: The invention provides methods for (a) treating decompensated heart failure; (b) treating compensated heart failure; (c) treating renovascular diseases and (d) treating end-stage renal diseases in a patient in need thereof comprising administering an effective amount of (i) at least one hydralazine compound or a pharmaceutically acceptable salt thereof, (ii)... Agent: Wilmerhale/nitromed

20080293726 - Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the... Agent: Heslin Rothenberg Farley & Mesiti PC

20080293728 - Complexes comprising alpha2-adrenergic receptor agonists and compositions: A complex comprises at least an α2-adrenergic receptor agonist and a compound that provides an opposite charge to a charge on the α2-adrenergic receptor agonist, wherein the complex is charge neutral as a whole and has a solubility in a range from about 0.3 μg/ml to about 2.5 mg/ml in... Agent: Bausch & Lomb Incorporated

20080293727 - Novel sulfonamide inhibitors of aspartyl protease: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and... Agent: Ropes & Gray LLP

20080293725 - Prognostic molecular markers: The present invention relates to the use of ecteinascidin 743 in patients having certain levels of molecular markers who can predict the outcome of chemotherapy, in particular in patients having low levels of BRCA1 expression.... Agent: King & Spalding

20080293729 - Composition and method of decreasing renal ischemic damage: A method of decreasing renal ischemic damage comprising a) identifying an organism having a kidney that is susceptible to renal ischemic damage from an ischemic event; and b) administering to the organism one or more than one effective dose of an agent prior to the ischemic event; where administering to... Agent: Sheldon Mak Rose & Anderson PC

20080293730 - Tricyclo substituted amides: Compounds of Formula (I): (formula) or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.... Agent: Eli Lilly & Company

20080293731 - Organic compounds: m

20080293732 - Substituted pyrazoles: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.... Agent: Philip S. Johnson Johnson & Johnson

20080293733 - Axl kinase inhibitors: Axl kinase inhibitory compounds are disclosed, as well as compositions and methods of using the same in the treatment of cancer and other conditions mediated by and/or associated with Axl kinase.... Agent: Seed Intellectual Property Law Group PLLC

20080293734 - Pharmaceutical compositions: Disclosed are useful pharmaceutical compositions.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080293735 - Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes: In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080293736 - Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents: The present invention provides novel quinolinone derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.... Agent: Fenwick & West LLP

20080293737 - Ion channel modulators and methods of use: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels.... Agent: Vertex Pharmaceuticals Inc.

20080293738 - Formulation of quinolinones: A pharmaceutical formulation, comprising: a compound of formula (I), a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof and at least one ingredient selected from the group consisting of (i) cellulose; (ii) silicon dioxide; (iii) magnesium stearate; and (iv) an... Agent: Novartis Corporate Intellectual Property

20080293739 - Compounds for modulating t-cells: p

20080293740 - Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders: The present invention provides a variety of methods of treatment of acid-sensing ion channel (ASIC) mediated pain, cough, and central nervous system disorders by ASICs inhibition with a series of pyrazinoylguanidine compounds represented by formula (I) as defined herein.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080293742 - Novel n-(fluoro-pyrazinyl)-phenylsulfonamides as modulators of chemokine receptor ccr4: The invention provides N-(fluoro-pyrazinyl)-phenylsulfonamides of formula (I) wherein R1-R5 are as defined in the specification; processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy... Agent: Morgan Lewis & Bockius LLP

20080293741 - Tricyclo substituted amides as glucokinase modulators: Compounds of Formula (I): (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.... Agent: Eli Lilly & Company

20080293743 - Novel hydantoin derivatives as metalloproteinase inhibitors: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.... Agent: Fish & Richardson P.C.

20080293744 - Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20080293745 - New amino-alkyl-amide derivatives as ccr3 receptor ligands: i

20080293746 - Combinations comprising pregabalin: The invention relates to a combination of pregabalin and 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-N-mesyl-7-[(4-methyl-2-pyridyl)amino]-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide, to pharmaceutical compositions containing the combination, and to the use of the combination in the treatment of pain.... Agent: Pfizer Inc.

20080293747 - Chemical synthesis of a highly potent epothilone: A highly active synthetic epothilone compound whose activity exceeds that of either epothilone EpoA or EpoB when assayed as a cytotoxic agent against a cancer cell line is disclosed as is a pharmaceutical composition containing the synthetic epothilone.... Agent: Husch Blackwell Sanders, LLP Welsh & Katz

20080293748 - Thioxanthine derivatives as myeloperoxidase inhibitors: wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia)... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080293749 - Pyrrolidine(thi)ones substituted by heterocyclic substituents in the 3-position: Pyrrolidine(thi)one compounds substituted by heterocyclic substituents in the 3-position, their preparation and use in pharmaceutical compositions, in particular as immunomodulators for treatment and/or inhibition of inflammatory and autoimmune diseases and haematological-oncological diseases.... Agent: Crowell & Moring LLP Intellectual Property Group

20080293750 - Susceptibility gene for myocardial infarction, stroke, paod and methods of treatment: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in... Agent: Marshall, Gerstein & Borun LLP

20080293751 - Tetralin and indane derivatives and uses thereof: n

20080293752 - Antiseptic body glide: An antiseptic body glide is a body glide with antiseptic properties. The antiseptic components do not interfere with other body glide components such as lubricants or preservatives. Additionally, the antiseptic body glide does not react unfavorably with latex. The antiseptic components do not have a bad taste or react with... Agent: Ortiz & Lopez, PLLC

20080293756 - 4,4-disubstituted piperidine derivatives: wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080293754 - Cyclopamine analogs: The invention provides novel derivatives of cyclopamine having the following formula:... Agent: Morrison & Foerster LLP

20080293755 - Heterocyclic cyclopamine analogs and methods of use thereof: The present invention relates to steroidal alkaloids that can be used in the treatment of hedgehog pathway related disorders, particularly cancer.... Agent: Morrison & Foerster LLP

20080293753 - Novel compounds: The invention relates to quaternary α-aminocarboxyamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, X, q and n are as defined in claim 1, for treating diseases and conditions mediated by modulation of voltage-gated sodium channels.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080293757 - Abca1 elevating compounds: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical... Agent: Michael J. Beck Cv Therapeutics, Inc

20080293758 - Combination of a steroid sulfatase inhibitor and an ascomycin: A combination of a steroid sulfatase inhibitor and an ascomycin, which combination is useful as a pharmaceutical.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20080293759 - Method for treating cancer based on the modulation of calcineurin: The present invention relates to methods for treating a haematopoietic tumor by administering a drug inhibiting calcineurin and/or the calcineurin/NFAT pathway, alone or in combination with other cancer therapy, pharmaceutical compositions useful in such methods, and screening methods for identifying a compound useful for treating a haematopoietic tumor.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080293760 - Gemifloxacin process and polymorphs: The present invention provides a novel process for the preparation of gemifloxacin and its pharmaceutically acceptable acid addition salts in high yield. The present invention also relates to novel polymorphs of gemifloxacin free base and its hydrates to the processes for their preparation and to pharmaceutical compositions comprising them. The... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080293761 - Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase: The present invention is directed to a novel form of a pyrrolopyridine-2-carboxylic acid amide of formula (I), which is an inhibitor of glycogen phosphorylase, compositions containing it and their use in therapy. The invention is also directed to processes for production of the novel form, novel intermediates used in said... Agent: Osi Pharmaceuticals, Inc.

20080293762 - Preventive and therapeutic medicament for gastroesophageal reflux disease: wherein R1 and R2 independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080293763 - Novel nitrogen-containing heteroaryl compounds and methods of use thereof: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.... Agent: Foley & Lardner LLP

20080293764 - Lpa receptor antagonist: (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by... Agent: Sughrue-265550

20080293765 - Alkylsulphonamide quinolines: h

20080293766 - Small-molecule inhibitors of the androgen receptor: wherein R1, R2, R3 and R8 are each independently hydrogen or C1-6 alkyl. R4 is absent or is hydrogen, C1-6 alkyl or C1-6 alkyl-OH. R5 is hydrogen, C1-6 alkyl or —NR6R7. R6 and R7 are each independently hydrogen or C1-6 alkyl, or are combined with the nitrogen to which they... Agent: Townsend And Townsend And Crew, LLP

20080293767 - 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity: This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an... Agent: Pfizer Inc.

20080293768 - Novel compounds derived from 5-thioxylose and their use in therapeutics: The invention relates to novel 5-thioxylose compounds, preferably derivatives of the 5-thioxylopyranose type, to the process for their preparation and to their use as active principles of drugs intended especially for the treatment or prevention of thrombosis or cardiac insufficiency.... Agent: Crowell & Moring LLP Intellectual Property Group

20080293769 - Polymorphs of a c-met/hgfr inhibitor: This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially... Agent: Pfizer Inc

20080293771 - Azacyclylbenzamide derivatives as histamine-3 antagonists: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor... Agent: Wyeth Patent Law Group

20080293770 - Compounds which have activity at m1 receptor and their uses in medicine: wherein R5 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; R6 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080293772 - Salts of picotamide: The invention relates to salts of picotamide (N,N′-bis-(3-picolyl)-4-methoxyisophthalamide) with strong acids, to pharmaceutical compositions containing picotamide salts, and to a method of treatment of cardiovascular and related diseases using picotamide salts. Particularly useful are picotamide hydrochloride and picotamide mesylate, preferably on a carbohydrate carrier such as hydroxymethylpropylcellulose.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080293773 - Amorphous esomeprazole hydrate: The present invention relates to a novel amorphous form of esomeprazole hydrate, to a process for its preparation and to a pharmaceutical composition containing it. Thus, tetrahydrofuran and water are added to esomeprazole potassium salt at 25-30 C, cooled to 20 C and then the pH is adjusted to 7.5-8.0... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080293774 - Treatment of the symptoms of bladder irritation: Use of a compound corresponding to formula (I), for obtaining a medicinal product for use in the treatment of the symptoms of bladder irritation.... Agent: Oliff & Berridge, PLC

20080293775 - Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease: The invention relates to substituted diphenylethers, -amines, -sulfides, and -methanes as useful pharmaceutical compounds for treating respiratory-disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Fish & Richardson P.C.

20080293776 - 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase): are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds... Agent: Novartis Institutes For Biomedical Research, Inc.

20080293777 - Weight loss treatment: The present invention relates to the use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one and other selenium-containing compounds for weight loss.... Agent: Heller Ehrman LLP

20080293778 - Arylvinylazacycloalkane compounds and methods of preparation and use thereof: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080293779 - Methods of treating humans undergoing injection of a contrast agent: A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080293780 - Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use: wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080293781 - Salicylic acid derivatives: The present invention refers to O-acyl salicylic acid derivatives (I) bearing a NO donor moiety, a process for their preparation and pharmaceutical compositions containing them. (I) wherein: D is ONO2 or (A).... Agent: Arent Fox LLP

20080293782 - 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors: are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds... Agent: Novartis Institutes For Biomedical Research, Inc.

20080293783 - Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents: Oxadiazolyl-phenoxyalkylisoxazoles and pharmaceutically acceptable salts thereof, compositions comprising oxadiazolyl-phenoxyalkylisoxazole compounds or pharmaceutically acceptable salts thereof and methods for using oxadiazolyl-phenoxyalkylisoxzazole compounds or pharmaceutically acceptable salts thereof as anti-picornaviral agents are described herein. The methods include using pleconaril as a prodrug for conversion to anti-picornaviral compounds in vivo.... Agent: Dann, Dorfman, Herrell & Skillman

20080293784 - Epothilones c, d, e and f, preparation and compositions: The present invention relates to epothilones C, D, E and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection.... Agent: Fitzpatrick Cella (bristol-myers)

20080293785 - Substituted benzothiazole kinase inhibitors: e

20080293786 - Novel 2-imino-1,3-thiazoline-based compounds and t-type calcium channel inhibitors containing the same: Novel 2-imino-1,3-thiazoline based compounds represented by Chemical Formula I, and T-type calcium channel inhibitors containing the compound are provided. The T-type calcium channel inhibitors according to the present invention are useful as a treating agent of diseases associated with over-expression of the T-type calcium channel.... Agent: LexyoumeIPGroup, LLC

20080293787 - Pharmaceutical compositions for poorly soluble drugs: The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080293788 - Methods and compositions for the treatment of pulmonary diseases: This invention related to methods of treating, preventing and managing various pulmonary diseases or disorders using formoterol in combination with calcium activated potassium channel openers. Pharmaceutical compositions comprising formoterol and calcium activated potassium channel openers are also disclosed.... Agent: Jones Day

20080293790 - Substituted aryl oximes: The present invention relates to substituted aryl oximes and methods of using them.... Agent: Wyeth Patent Law Group

20080293789 - Valsartan formulations: The present invention relates to a new pharmaceutical formulation in the form of a tablet consisting of valsartan as an active agent, pregelatinized starch, microcrystalline cellulose.... Agent: Arent Fox LLP

20080293791 - Valsartan salts: The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.... Agent: Novartis Corporate Intellectual Property

20080293794 - Diaryltriazolmethylamine derivatives, preparation and therapeutic use thereof: e

20080293793 - Fungicidal mixtures for wood preservation: Using synergistically effective mixtures comprising triadimefon and/or triadimenol and at least one further known fungicidally active compound, it is possible to protect industrial materials, in particular wood, against attack, damage and/or destruction by biological pests, in particular by wood-destroying fungi.... Agent: Lanxess Corporation

20080293792 - Tocopherol derivatives and uses thereof: wherein n is an integer of 6 to 13, R1 is hydrogen, a silyl ether or acetate, R2 is an optionally substituted nitrogen-containing heterocycle or a polycyclic nitrogen-containing heterocycle; and pharmaceutically acceptable salts thereof are provided. A method for synthesizing the compounds is also provided. The tocopherol derivatives are capable... Agent: Dennison, Schultz & Macdonald

20080293795 - Combination therapy with parp inhibitors: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with temozolomide (TMZ).... Agent: Paul D. Yasger Abbott Laboratories

20080293796 - Parenteral and oral formulations of benzimidazoles: Provided herein are drug delivery systems comprising nanosuspension formulations suitable for parenteral delivery to a subject. The nanosuspension formulations may comprise a benzimidazole derivative, e.g., mebendazole, and surface stabilizers, such as block copolymer(s), e.g., Pluronic F108, and surfactant(s), e.g., Tween 80, and, optionally, water. Provided are methods for defining nanosuspensions... Agent: Benjamin Aaron Adler Adler & Associates

20080293797 - Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments: The present invention relates to Cycloalkane-substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff, Ltd.

20080293798 - Fungicidal mixtures comprising substituted 1-methylpyrazol-4-ylcarboxanilides: in a synergistically effective amount, methods for controlling harmful fungi using mixtures of at least one compound I and at least one active compound II and the use of the compound(s) I with active compounds II for preparing such mixtures, and also compositions and seed comprising such mixtures.... Agent: Hutchison Law Group PLLC

20080293800 - Cytotoxic compounds and conjugates: The present disclosure provides cytoxic compounds useful as drugs or prodrugs and to drug-cleavable substrate conjugates where the drug and cleavable substrate are optionally linked through a self-immolative linker.... Agent: Medarex C/o Darby & Darby P.C.

20080293799 - Liver function ameliorant: The present invention relates to a liver function ameliorant containing orniplabin as an active ingredient thereof.... Agent: Birch Stewart Kolasch & Birch

20080293802 - Chemical compounds: The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080293803 - Melatonin daily dosage units: The present invention relates to a disposable container for a medicament or cosmetic agent for topical application, containing a single dose of melatonin or of a melatonin derivative which corresponds to a locally effective dose but which does not cause any systemic effect.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080293801 - Solid amorphous dispersions of an mtp inhibitor for treatment of obesity: A composition comprises a solid amorphous dispersion comprising (S)—N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-methyl-5-[4′-(trifluoromethyl)[1,1′-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and a polymer.... Agent: Pfizer Inc.

20080293804 - Pharmaceutical nasal spray formulation of acetaminophen (paracetamol): The invention in question is a novel pharmaceutical formulation that comprises a one percent weight by volume Paracetamol in a phosphate buffer adjusted to pH 7.4 by addition of few drops of 1.0 N NaOH. The concentrations of the ingredients were chosen such that the resulting solution is isotonic with... Agent: Muwaffak J Haddadin

20080293805 - Drug delivery system and the preparing method thereof: A drug delivery system comprises a liposome and at least one charged nanoparticle. The liposome has at least an internal lipid layer and an external lipid layer, wherein the internal lipid layer forms an interior space for accommodating a drug. The charged nanoparticle is reversibly associated with an exterior surface... Agent: Sinorica, LLC

20080293806 - Odor reduction compositions: An odor-reducing composition for counteracting malodour in which the composition includes an odor reducing material of the type phenyl ethyl methyl ether, Cyprisate, Camonal and paracresyl methyl ether and a method for counteracting malodour employing such a composition.... Agent: Morgan Lewis & Bockius LLP

20080293807 - Skin cosmetic and wrinkle-reducing agent: It is intended to provide a skin cosmetic and a wrinkle-reducing agent which are excellent in improving wrinkles caused by photoaging. Namely, a skin cosmetic and a wrinkle-reducing agent containing isosorbide which is represented by the following structural formula (1).... Agent: Foley And Lardner LLP Suite 500

20080293808 - Non-steroidal androgen receptor modulators, preparation process, pharmaceutical composition and use thereof: Non-steroidal androgen receptor modulating compounds of the general formula (I), their pharmaceutically acceptable salts, preparation process and pharmaceutically compositions containing the said compounds are disclosed. Such compounds of the general formula (I) or their pharmaceutically acceptable salts can be used for preparing non-steroidal medicines to treat and/or prevent conditions or... Agent: Nixon & Vanderhye, PC

20080293809 - Pest control formulation: The present invention relates to a pest control composition that includes a pest control active ingredient and a polyoxypropylene-polyoxyethylene ether of a long chain fatty alcohol as an agent to reduce or eliminate paraesthesia of the active ingredient to a warm blooded mammal. The system releases the active ingredient efficiently... Agent: Jacqueline S Larson

20080293810 - Multi-dose concentrate esmolol with benzyl alcohol: Disclosed are concentrate esmolol injection essentially free from other related esters of esmolol and diluted esmolol compositions. The concentrate esmolol formulation includes from about 25-1000 mg/ml of esmolol and about 1-25% w/v of benzyl alcohol and the combination thereof. The compositions can also be used as multi-dose compositions. The present... Agent: Baxter Healthcare Corporation

20080293811 - External preparation for the the skin: s

20080293812 - Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates: Pamoic acid or its derivatives of formula (I) are used to treat diseases characterized by deposits of amyloid aggregates.... Agent: Nixon & Vanderhye, PC

20080293813 - Compositions and methods: Gaseous nitric oxide (NO) can be delivered to a mammal for prophylactic or therapeutic purposes using a composition capable of delivering NO, comprising a compound capable of forming a reversible bond or association with NO. Methods for the manufacture and use of said composition are disclosed.... Agent: Morrison & Foerster LLP

20080293814 - Concentrate esmolol: A concentrate esmolol formulation is provided that is safer than current concentrate (e.g., 250 mg/ml) esmolol compositions. The concentrate esmolol formulation can include from about 40-60 mg/ml of esmolol hydrochloride. The concentrate esmolol composition allows a practitioner the flexibility of choosing a bolus volume for direct injection to a patient... Agent: Baxter Healthcare Corporation

20080293815 - Hca for improved hdl serum lipids profile: Described herein are compositions and methods for increasing serum high-density cholesterol lipoprotein (HDL) levels in an individual in need thereof comprising orally administering an effective amount of HCA.... Agent: Foley & Lardner LLP

20080293816 - Use of 2,5-dihydroxybenzenesulphonic acid in the production of medicaments for the treatment of angiodependent diseases such as cancer and psoriasis: The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present... Agent: Ladas & Parry LLP

20080293817 - Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.... Agent: Buchanan, Ingersoll & Rooney PC

20080293818 - Regulator of physiological function of ghrelin and use thereof: A regulator for regulating physiological functions, such as activity of increasing an intracellular calcium ion concentration, activity of promoting growth hormone secretion, activity of promoting eating, regulatory activity relating to fat accumulation, activity of ameliorating heart function and activity of stimulating gastric acid secretion, of ghrelin, which regulator comprises a... Agent: Drinker Biddle & Reath (dc)

20080293819 - Di-fluoro containing compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP

20080293820 - Methods for improving physical function in fibromyalgia: Methods for improving physical function in fibromyalgia syndrome by administering an NSRI such as milnacipran as disclosed.... Agent: Darby & Darby P.C.

20080293821 - Cooling compositions: Disclosed are improved cooling compositions comprised of N-(2-hydroxyethyl)-2,3-dimethyl-2-isopropylbutyramide and at least one other cooling agent. The cooling compositions may be used alone or in products such as a chewing gum or a confection.... Agent: Qaroma Inc. Subsidary Of Chemicals Incorporated

20080293822 - Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use: The invention provides novel arylbicyclo[3.1.0]hexylamines, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.... Agent: Jeffrey J. King Esq. Black Lowe & Graham PLLC

20080293823 - Methods and compositions for treating sleep-related breathing disorders: Provided herein are methods of treating a sleep-related breathing disorder, such as obstructive sleep apnea, comprising the administration of O-desmethylvenlafaxine or duloxetine.... Agent: Jones Day

20080293824 - Pesticidal substituted piperidines: The invention relates to the use of phenylether derivatives of formula (I), to compositions thereof for the control of pests, including arthropods and helminths.... Agent: Frommer Lawrence & Haug

20080293825 - Hydroalcoholic antimicrobial composition with skin health benefits: The invention pertains to an alcohol based antimicrobial skincare composition. The invention also pertains to an alcohol based antimicrobial skincare composition with skin health benefits including moisturization and skin barrier maintenance effects. The invention further pertains to an alcohol based antimicrobial skincare composition that is a stable emulsion that has... Agent: Ecolab Inc.

20080293826 - Cosmetic compositions with ethoxylated urethane: A cosmetic composition is provided which includes petrolatum, water, and ethoxylated urethane. This composition retains stable viscosity without being sticky or tacky and can easily be rubbed into skin.... Agent: Unilever Patent Group

20080293827 - Temperature and ph sensitive block copolymer and polymeric hydrogels using the same: Disclosed is a block copolymer formed by coupling the following components with each other: (a) a copolymer (A) of a polyethylene glycol (PEG) type compound with a biodegradable polymer; and (b) at least one oligomer (B) selected from the group consisting of poly(β-amino ester) and poly(amido amine). A method for... Agent: Sughrue Mion, PLLC

20080293828 - Use of copolymers as solubilizers for slightly water-soluble compounds: s

20080293829 - Novel compounds: This invention relates to newly identified ester-linked gemini surfactant compounds, to the use of such compounds and to their production. The invention also relates to the use of the ester-linked gemini surfactant compounds to facilitate the transfer of polynucleotides into cells.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080293830 - Method for activating efferent sympathetic nerves innervating adipose tissues to improve obesity and symptoms associated therewith: A method for activating an efferent sympathetic nerve innervating an adipose tissue and improving obesity-associated symptoms is provided, comprising stimulating an afferent vagal nerve from the liver without directly enhancing peroxisome proliferator-activated receptor (PPAR)-γ2 function in the liver.... Agent: Barnes & Thornburg LLP

20080287342 - Compositions comprising modified collagen and uses therefor: The invention provides modified collagen and related therapeutic and diagnostic methods.... Agent: Edwards Angell Palmer & Dodge LLP

20080287341 - Treatment of vascular abnormalities using nanoparticles: Vascular abnormalities in a patient are treated by administering a therapeutically effective amount of an agent that reduces angiogenesis. The agent comprises an vascular leakage angiogenic inhibitor and/or vascular leakage angiogenic inhibitor expression plasmid/vector encapsulated by a biocompatible nanoparticle.... Agent: Greenberg Traurig LLP (la)

20080287343 - Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes: This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080287344 - Use of amino acids for making medicines for treating insulin resistance: The invention concerns the use of monohydroxy or polyhydroxy amino acids, and the lactone forms thereof for making medicines with insulin-analogue and/or insulin-sensitizing effects on peripheral tissues targeted by insulin, and more particularly the use thereof for making medicines for treating and preventing insulin-resistance.... Agent: Clark & Elbing LLP

20080287346 - Bioactive peptides: The present invention provides a cytotoxic 7 to 25-mer peptide with three or more cationic residues which has one or more non-generic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and... Agent: Crowell & Moring LLP Intellectual Property Group

20080287345 - Polymyxin derivatives and uses thereof: The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080287347 - Novel lipopeptides as antibacterial agents: The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.... Agent: Intellectual Property Department Cubist Pharmaceuticals, Inc.

20080287350 - Aequorin-containing compositions and methods of using same: Compositions containing aequorin and methods for their use in preventing and/or alleviating symptoms and disorders related to calcium imbalance are provided by the present invention.... Agent: Godfrey & Kahn S.c.

20080287355 - Amylin and amylin agonists for treating psychiatric diseases and disorders: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080287352 - Anti-histone h1 monoclonal antibody and hybridoma for the production thereof: The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080287364 - Bitter taste receptors: The present invention relates to bitter-taste receptors and their role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block, bitter taste transduction, or enhance bitter taste response.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080287359 - Cadherin-11-mediated modulation of hair growth: The present invention provides for methods of inhibiting hair growth, comprising decreasing the level of CAD1 1 mRNA and/or protein in hair follicle cells of a subject. The present invention further provides for methods of promoting hair growth, comprising increasing the level of CADI 1 mKNA and/or protein in hair... Agent: Baker Botts L.L.P.

20080287356 - Chimeric proteins, their preparation and pharmaceutical compositions containing them: The present invention relates to a chimeric protein comprising a cell-targeting agent and a Yersinia outer protein, connected by a translocating polypeptide. The invention further relates to the preparation and use of such chimeric protein.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080287362 - Compositions and methods for the detection of trypanosoma cruzi infection: Compositions comprising fusion polypeptides of T. cruzi epitopes are provided, together with methods for the use of such compositions in the diagnosis of T. cruzi infection and in screening blood supplies. Diagnostic kits comprising such compositions are also provided.... Agent: Speckman Law Group PLLC

20080287360 - Compositions and methods for treating malaria with cupredoxin and cytochrome: The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by P. falciparum. The invention provides isolated... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080287361 - Compositions and methods of using crmp-1 and its fragments for treating cancer: The present invention discloses a method for treating cancer by using hCRMP1 and/or active fragments thereof, as well as the active fragments of hCRMP1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer. The method can also be used prior to, or in combination with, the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080287357 - Conjugate comprising p21 protein for the treatment of cancer: The P21 protein is used as a medicament in the treatment of cancer. A conjugate comprises a first region comprising the P21 protein, or a homologue or functional fragment thereof; and a second region comprising a translocation factor.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080287365 - Drug and method for proliferating natural killer cells: Natural Killer (NK) cells are obtained by administering a Toll-like receptor ligand such as polyinosinic-polycytidylic acid into the peritoneal cavity of an animal to which lactoferrin has been administered to proliferate NK cells in the peritoneal cavity and collecting NK cells from the peritoneal cavity.... Agent: Knobbe Martens Olson & Bear LLP

20080287349 - Fibroblast growth factor 20 and methods of use thereof: The present invention relates to compositions and methods for preventing and treating a disease (e.g., a joint disease, ischemic stroke, hemorrhagic stroke, trauma, spinal cord damage, heavy metal or toxin poisoning, or neurodegenerative diseases). More particularly, the present invention provides methods for preventing and/or treating a disease (e.g., a joint... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080287351 - Nfkb transcriptional activity inhibitory agent and anti-inflammatory agent and a steroid action enhancing agent: An agent is characterized by containing MTI-II, especially a nucleic acid sequence of SEQ ID NO: 1, or a peptide of SEQ ID NO: 2. This MTI-II peptide is preferably a peptide containing at least an acidic amino acid domain (SEQ ID NO: 3). Further, a steroid agent such as... Agent: Marshall, Gerstein & Borun LLP

20080287363 - Novel cc-chemokine antagonists: A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immunomodulatory compounds and in the treatment or prevention of CC-chemokine-related diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080287353 - Peptides and proteins for early liver development and antibodies thereto: Early developing stage-specific liver proteins and the genes coding for them that have been isolated and sequenced are provided, and these genes and proteins can be utilized to diagnose and/or treat a wide variety of liver disorders and other ailments. Since the early developing liver proteins of the invention arise... Agent: Stites & Harbison PLLC

20080287354 - Prosaposin as a neurotrophic factor: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.... Agent: Kenyon & Kenyon LLP

20080287358 - Regulatory t cell mediator proteins and uses thereof: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated Treg-sTNE Proteins,... Agent: Licata & Tyrrell P.C.

20080287348 - Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalopathies: The present invention relates to a soluble hybrid protein, comprising at least a first polypeptide sequence derived from a prion protein PrPc that is capable of binding a protein responsible for transmissible spongiform encephalitis (PrPSc), and a second polypeptide sequence (tag), wherein said hybrid protein does not comprise a functional... Agent: Marshall, Gerstein & Borun LLP

20080287367 - Non-toxic biofilm inhibitor: The present invention relates to a composition and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain of Pseudomonas aeruginosa type IV pilin, which binds to an abiotic surface (e.g., steel, plastic) with high affinity... Agent: Greenlee Winner And Sullivan P C

20080287366 - Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus: and a substituted β-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human... Agent: John P. White Cooper & Dunham LLP

20080287368 - Methods and compositions for the prevention and treatment of kidney disease: The invention provides compositions for preventing or treating kidney disease comprising vitamin E, vitamin C, and a carotenoid and methods for preventing and treating kidney disease comprising administering such compositions to an animal susceptible to or suffering from kidney disease. In a preferred embodiment, the composition is admixed with one... Agent: Colgate-palmolive Company

20080287369 - Compositions and methods for viscosupplementation: The invention provides viscosupplementation compositions that include hyaluronic acid, or a polymer thereof and tribonectin. Such compositions are useful for the lubrication and chondroprotection of mammalian joints.... Agent: Clark & Elbing LLP

20080287370 - Boronic acid salts useful in parenteral formulations: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)—Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080287371 - Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex: The present invention relates to novel conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds are useful as therapeutics for a range of gastrointestinal disorders, in particular those in which suppression or inhibition of the migrating... Agent: Myers Bigel Sibley & Sajovec

20080287372 - Use of ketogenic compounds for treatment of age-associated memory impairment: This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention... Agent: Swanson & Bratschun, L.L.C.

20080287374 - Breast cancer-resistant protein inhibitor: i

20080287373 - Topical skin treating kits: A kit comprising a soap-free cleanser and a topical composition which comprises clindamycin or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier, formulations and packages thereof, and methods of using the same to treat various skin disorders.... Agent: Nath & Associates

20080287375 - Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof: The invention comprises compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions containing the compounds or prodrugs of the compounds. The invention also comprises animal models and methods of making the animal models for studying diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or... Agent: Woodcock Washburn LLP

20080287377 - Composition based on triethyl citrate for the prevention of enzymatic hydrolysis of triglycerides: The invention concerns a composition for topical use for the protection of triglycerides against enzymatic hydrolysis, which contains triethyl citrate as an active ingredient either pure or in combination with some synergists. The triethyl citrate is in a quantity in weight expressed as a percentage from 0.1 to 99.9, preferably... Agent: Mcglew & Tuttle, PC

20080287376 - Ketolide derivatives as antibacterial agents: The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp. Chlamydia spp.,... Agent: Ranbaxy Inc.

20080287378 - Solid state forms of 5-azacytidine and processes for preparation thereof: The present invention provides novel crystalline forms of 5-deazacytidine, and pharmaceutical compositions comprising these novel forms. The invention also provides methods for the preparation of the novel forms and compositions.... Agent: Kenyon & Kenyon LLP

20080287380 - Antisense oligonucleotides against cpla2, compositions and uses thereof: Antisense oligonucleotides against cPLA2 are provided, which are capable of inhibiting cPLA2 expression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases. The antisense oligonucleotides or compositions comprising the same... Agent: Marsteller & Associates

20080287388 - Human g-protein coupled receptor: A human G-protein coupled receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for identifying antagonists and agonists to such polypeptide. Antagonists and agonists may be used therapeutically to inhibit or... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080287385 - Inhibitor oligonucleotides and their use for specific repression of a gene: A double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3′ or 5′ ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or... Agent: Ip Group Of Dla Piper US LLP

20080287381 - Injectable agent for the targeted treatment of retinal ganglion cells: The present invention relates to the targeted treatment of retinal ganglion cells (RGC).... Agent: Klarquist Sparkman, LLP

20080287387 - Method for producing sterile polynucleotide based medicaments: The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based medicaments. A suitable method of production disclosed herein additionally comprises cold filtering a mixture of a polynucleotide,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080287384 - Methods of identifying agents having antiangiogenic activity: Provided are assays and methods of identifying antiangiogenic agents including contacting an endothelial cell with a putative antiangiogenic agent and assaying for activation of Rap-1 in the endothelial cell. Also provided are methods of inhibiting angiogenesis and treating conditions associated with improper angiogenesis. Compositions comprising activators of Rap-1 and methods... Agent: Michael Best & Friedrich LLP

20080287383 - Nucleic acid compounds for inhibiting erbb gene expression and uses thereof: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ERBB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an... Agent: Nastech Pharmaceutical Company Inc Mdrna, Inc.

20080287389 - Nucleoside analogs in combination therapy of herpes simplex infections: A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or peniclovir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.... Agent: Novartis Corporate Intellectual Property

20080287379 - Oligonucleotide complex compositions and methods of use as gene alteration tools: Compositions and methods of treatments of cells are provided for altering the phenotype of a cell by administering an oligonucleotide complex to the cell, the complex having two strands and chemical modifications.... Agent: Beattie, Ingrid A. Mintz, Levin, Cohn, Ferris, Glovsky And Popeo

20080287382 - Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a... Agent: Cooper & Dunham, LLP

20080287386 - Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases: The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The... Agent: Cooper & Dunham, LLP

20080287390 - Pyrazolidinol compounds: The invention provides the use of an optionally hydroxyl-protected 4-hydroxy or hydroperoxy-3,5-dioxopyrazolidine or an equivalent wherein a pyrazolidine ring attached oxygen is replaced by a sulphur, or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in drug therapy or prophylaxis. Additionally, the invention provides a... Agent: Bacon & Thomas, PLLC

20080287391 - Cell fusion promoter and utilization of the same: It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell... Agent: Edwards Angell Palmer & Dodge LLP

20080287392 - Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate: This invention relates to wound-healing pharmaceutical or cosmetic (anti-skin aging) compositions in the form of a cream based on amino acids and sodium hyaluronate.... Agent: Steinfl & Bruno

20080287393 - External skin composition: i

20080287394 - Hiv integrase inhibitors: Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and... Agent: Merck And Co., Inc

20080287395 - Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions: The use of certain synthetic phospholipids to preserve pharmaceutical compositions from microbial contamination is described. The synthetic phospholipids have unique molecular arrangements wherein a phosphate group is linked to a quaternary ammonium functionality via a substituted-propenyl group, and the quaternary ammonium functionality is further linked to at least one long... Agent: Alcon

20080287398 - Cold menthol receptor-1 antagonists: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or... Agent: Philip S. Johnson Johnson & Johnson

20080287396 - Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections: The present invention relates to phosphonated fluoroquinolones, antibacterial analogs thereof, and methods of using such compounds. These compounds are useful as antibiotics for prevention and/or the treatment of bone and joint infections, especially for the prevention and/or treatment of osteomyelitis.... Agent: Merchant & Gould PC

20080287397 - Pyrrolopyrimidine derivatives substituted with cyclic amino group: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence,... Agent: Sughrue Mion, PLLC

20080287400 - Low dosage forms of risedronate or its salts: Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080287399 - Substituted aminopyridines and uses thereof: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080287401 - Methods for synthesizing and purifying aminoalkyl tetracycline compounds: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080287402 - Use of a glial attenuator to prevent amplified pain responses caused by glial priming: The use of a glial attenuator, such as ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), to prevent the negative consequences of glial priming is described. In particular, the present invention is directed to a method of treating a subject with ibudilast to prevent amplified pain responses to inflammation or injury as a result of glial... Agent: Robins & Pasternak LLP

20080287403 - Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events: Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080287404 - High purity 17alpha-cyanomethyl-17beta-hydroxy-estra-4,9-diene-3- one and process for the syntheses thereof: The invention relates to a new process for the synthesis of high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain... Agent: K.f. Ross P.C.

20080287406 - Compositions and methods for treating medical conditions: The invention features methods, compositions, and kits for the treatment of pain, pruritus, immunoinflammatory disorders, musculoskeletal disorders, and the reduction of serum C reactive protein (CRP) in a patient having a disease or conditions associated with an increased CRP level. The methods, compositions, and kits of the invention provide for... Agent: Clark & Elbing LLP

20080287405 - Compositions and methods relating to protein kinase inhibitors: The present invention relates to compounds useful for treating fibrotic disorders, methods for their discovery, and their therapeutic use. In particular, the present invention provides pyrazolopyrimidine compounds and related compounds and methods of using pyrazolopyrimidine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with... Agent: Casimir Jones, S.c.

20080287407 - Nitric oxide releasing pyruvate compounds, compositions and methods of use: The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived... Agent: Wilmerhale/dc

20080287408 - Endometriosis treatment: A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the... Agent: Kv Pharmaceutical Company

20080287412 - Therapeutic combination of amlodipine and benazepril/benazeprilat: p

20080287413 - New crystalline forms: There are provided crystalline forms of the compounds Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)-Aze-Pab(OMe) and Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)-Aze-Pab(OH), pharmaceutical compositions containing them, processes for obtaining them and their use in medical treatment.... Agent: Morgan Lewis & Bockius LLP

20080287411 - Optically active dihydropyridine derivative: The optically active compound (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5-isopropyl ester or a pharmacologically acceptable salt thereof, and a method using the compound or its salt to treat circulatory diseases.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080287409 - Phenyl and pyridinyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceutical compositions: in which the R-group substituents are defined herein. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and de-myelinating and other neurodegenerative disorders of the central and peripheral nervous... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080287410 - Pyrimidine derivatives useful as inhibitors of pkc-theta: wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080287415 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: e

20080287414 - Mitotic kinesin inhibitors: The present invention relates to tricyclic pyrazoles according to Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer... Agent: Merck And Co., Inc

20080287416 - Organic compounds: e

20080287417 - Pharmaceutical compositions comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer: Solid composition comprising (a) an anionic surfactant in combination with a water-soluble and basic polymer, or (b) a cationic surfactant in combination with a water-soluble and acidic polymer, and (c) at least one poorly water-soluble pharmaceutically active ingredient, and solid or liquid dosage forms, especially tablets, coated tablets, capsules or... Agent: Novartis Corporate Intellectual Property

20080287418 - Extended release compositions and methods for their manufacture: Extended release formulations of quetiapine and its pharmaceutically salts, and methods for manufacture of the formulations, may include the use of polymers selected for their physical and chemical characteristics. The formulations may include polymers selected to cause solid dosage forms of the formulations to conform to preselected quetiapine release criteria.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080287419 - Apoptosis promoters: Compounds which inhibit the activity of anti-apoptotic family protein members, compositions containing the compounds and methods of treating diseases during which occur expression one or more than one of an anti-apoptotic family protein member are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20080287421 - 3,3-spiroindolinone derivatives: m

20080287420 - Cyclopamine lactam analogs and methods of use thereof: The present invention relates to steroidal alkaloids useful in the treatment of hedgehog pathway related disorders, particularly cancer.... Agent: Morrison & Foerster LLP

20080287422 - Constrained compounds as cgrp-receptor antagonists: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and... Agent: Louis J. Wille Bristol-myers Squibb Company

20080287423 - Use of azapaullones for preventing and treating pancreatic autoimmune disorders: This invention relates to the use of azapaullones, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA and neurodegenerative disorders.... Agent: Millen, White, Zelano & Branigan, P.C.

20080287424 - Azolylacylguanidines as beta-secretase inhibitors: i

20080287425 - Method for controlling chinch bugs: The present invention relates to a method for controlling chinch bugs comprising introducing to a locus where chinch bug control is needed or expected to be needed a composition comprising a nitroguanidine insecticide.... Agent: Patent Administrator Fmc Corporation

20080287426 - Method of inducing resistance to harmful fungi: The present invention relates to a method of inducing plant tolerance to harmful fungi comprising the application to the plants, the soil, in which the plant grows or is to be grown and/or the seeds of the plant, of an effective amount of an active compound that inhibits the mitochondrial... Agent: Birch Stewart Kolasch & Birch

20080287427 - Bicyclic amides as kinase inhibitors: The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising en a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the... Agent: Novartis Institutes For Biomedical Research, Inc.

20080287429 - Dissolution of arterial cholesterol plaques by pharmacologically induced elevation of endogenous bile salts: A group of pharmaceutical substances induce elevation of endogenous bile salts and acids via different mechanisms. The elevated circulating bile salts exert a beneficial effect in atherosclerosis by acting both as atherolytic and antiatherogenic agents. The result of the elevated circulating endogenous bile salt is the dissolution of cholesterol/lipidic aggregates... Agent: Mcdermott Will & Emery LLP

20080287428 - Novel heterocyclidene acetamide derivative: (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO2 group, or the like; R2 represents halogen, amino, a hydrocarbon group, an... Agent: Oliff & Berridge, PLC

20080287430 - Furan compounds useful as ep1 receptor antagonists: h

20080287431 - Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient:

20080287433 - derivatives of artemisinin, and their uses in the treatment of malaria:

20080287432 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-AbI, Aurora-A, SGK,... Agent: Genomics Institute Of The Novartis Research Foundation

20080287434 - New amino-alkyl-amide derivatives as ccr3 receptor ligands: e

20080287435 - Active ingredient combinations having insecticide and acaricide properties: The novel active compound combinations of certain cyclic ketoenols and ethiprole have very good insecticidal and acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080287436 - Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080287438 - Agent for preventing or treating neuropathy: The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula: wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s); B is an optionally substituted... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080287437 - Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors: e

20080287439 - Pyrimidine compounds: The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080287440 - Novel antifungal triazole derivatives: Disclosed herein are antifungal triazole derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The triazole derivatives of Chemical Formula 1 or pharmaceutically acceptable salts thereof according to the present invention have excellent inhibitory activity against a broad spectrum of fungi, in... Agent: Sughrue Mion, PLLC

20080287441 - Alpha-(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents: s

20080287442 - Organic compounds: 14-O—[(((C1-6)Alkoxy-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O—[(((C1-6)Mono- or dialkylamino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Hydroxy-(C1-8)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C0-5)-alkyl)-phenylsulfanyl)-acetyl]-mutilins 14-O-[((Guanidino-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Ureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Thioureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Isothioureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins and their use as pharmaceuticals.... Agent: Knobbe Martens Olson & Bear LLP

20080287443 - Treatment of subgingival pocket infections: Use of a morpholino compound having the general formula (I) wherein R1 is a straight or branched alkyl group containing (8) to (16) carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing (2) to (10) carbon atoms, substituted... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080287444 - Pyrazole compounds useful as protein kinase inhibitors: wherein Z1, Z2, and Z3 are as described in the specification; Q is —S—, —O—, —N(R4)—, or —CH(R6)—; R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; and R2 and R2′ are as described... Agent: Tina Powers Vertex Pharmaceuticals Inc.

20080287445 - Prokineticin 2 receptor antagonists: e

20080287449 - Aza-tripeptide hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080287448 - Diacyl indazole derivatives as lipase and phospholipase inhibitors: i

20080287447 - Methods for preparing eszopiclone: Methods for the preparation of crystalline eszopiclone free base in water, in the absence of organic solvents, are provided. The methods are more environmentally acceptable than prior art methods, and produce eszopiclone free base essentially free of residual organic solvent.... Agent: Kenyon & Kenyon LLP

20080287446 - Sulfonyl containing compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP

20080287451 - Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as... Agent: Morrison & Foerster LLP

20080287450 - Novel substituted tetracyclic tetahydrofuran, pyrrolidine and tetrahydrothiophene derivatives: a

20080287452 - Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system: The present invention relates to heteroaryl/aryl pyrimidine analogs, methods of making aryl/heteroaryl pyrimidine analogs, compositions comprising a aryl/heteroaryl pyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a heteroaryl/aryl pyrimidine analog.... Agent: Wyeth Patent Law Group

20080287453 - Piperazine compounds useful as antagonists of c-c chemokines (ccr2b and ccr5) for the treatment of inflammatory diseases: wherein P is an optionally substituted aryl or heteroaryl group; W is an optionally substituted 6 or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 independently selected from Oxygen and Nitrogen, X is selected from Oxygen, Nitrogen and Sulphur; L is an optional C1-4 linker; and Q is an... Agent: Morgan Lewis & Bockius LLP

20080287454 - Cxcr4 antagonists: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors... Agent: Morrison & Foerster LLP

20080287455 - Sulfanyl substituted phenyl methanones: e

20080287456 - Oral therapeutic compound delivery system: The present invention relates generally to therapeutic formulations. More particularly, this present invention provides an oral delivery system for a therapeutic compound that is a base, a salt of a base or an amphoteric compound or a salt of a amphoteric compound with pharmacological, physiological or biochemical activity or a... Agent: Kenyon & Kenyon LLP

20080287458 - Dihydroquinone and dihydronaphthridine inhibitors of jnk: e

20080287457 - Inhibitors of akt activity: The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted... Agent: Merck And Co., Inc

20080287459 - Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia: The present invention is related to an orally administered pharmaceutical composition for the prevention of hair loss; having the effects of epilation, hair toning, and hair growth; and for the treatment of female hirsutism and benign prostatic hyperplasia. The composition of the present invention is non-steroidal and is advantageous in... Agent: The Webb Law Firm, P.C.

20080287460 - New compounds 835: e

20080287462 - New compounds 834:

20080287461 - Pyridinone derivatives against malaria: 4-pyridone derivatives of Formula (1) and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080287463 - Pyrazolopyrimidines: p

20080287464 - Depot formulations: Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more... Agent: Durect Corporation Thomas P. Mccracken

20080287466 - 4-amino-2,3-disubstituted thieno [2,3,d]pyrimidines and pharmaceutical compositions thereof: Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080287465 - Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof: Acrylic n-hydroxy imides and their use in pharmaceutical compositions and in the inhibition of flap endonuclease are disclosed.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080287467 - Therapeutic agent for respiratory diseases: The invention provides a therapeutic agent for respiratory diseases, which is based on a new activity mechanism of the antagonism to the P2X4 receptor and by which fewer adverse activities of the existing β-stimulants on the cardiovascular system can be expected. The therapeutic agent of the invention is antagonistic to... Agent: Sughrue-265550

20080287468 - Purine and imidazopyridine derivatives for immunosuppression: The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas:... Agent: Heslin Rothenberg Farley & Mesiti PC

20080287469 - Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation: The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting leukocyte accumulation comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) and phosphoinositide 3-kinase gamma (PI3Kγ) activities in endothelial cells. The disclosed methods may be used to treat individuals having an inflammatory condition where leukocytes are found... Agent: Morrison & Foerster LLP

20080287470 - Presentation of an antiviral pharmaceutical composition: A new presentation of an antiviral pharmaceutical composition in solution form comprising as an active agent, aciclovir in an amount of about 5% by weight; a solvent in an amount of from about 10 to 20% by weight; a solubilizing agent in an amount of from about 1.5 to 5.0%... Agent: Birch Stewart Kolasch & Birch

20080287471 - 4'-substituted carbovir and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity: The application relates to compounds with activity against infectious viruses. Accordingly, in one embodiment the invention provides a compound of the invention which is a compound of Formula I: (I) wherein: B is adenine, guanine cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropuriine, 2,6-diaminopurine, hypoxanthine,... Agent: Viksnins Harris & Padys Pllp

20080287472 - Fungicides: e

20080287473 - Novel molecules for regulating cell death: The present invention provides compounds capable of regulating apoptosis, e.g., via regulating mitochondrial fission or fusion. The present invention also provides methods of screening for compounds capable of regulating apoptosis and methods of treating conditions association with apoptosis.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080287474 - Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones: The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080287475 - 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer: This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.... Agent: Astrazeneca R&d Boston

20080287476 - Administration of dipeptidyl peptidase inhibitors: Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.... Agent: Mitchell R. Brustein

20080287477 - Novel compounds as modulators of ppar: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080287479 - Inhibitors of serine palmitoyltransferase: useful in the inhibition or modulation of serine palmitoyl transferase and their use in methods of treatment or amelioration of type 2 diabetes, type 1 diabetes, insulin resistance, the effects of obesity, metabolic syndrome (sometimes referred to as Syndrome X), impaired glucose tolerance, Cushing's disease, cardiovascular disease, prothrombotic conditions, myocardial... Agent: Pfizer Inc.

20080287478 - Nociceptin analogues and uses thereof: The present invention relates to nociceptin analogues and uses thereof to modulate biological functions. In one aspect, the invention provides modified triazo-spiro compounds that include at least one specialized chemical group that is bound to the compounds. The invention has a wide range of applications including providing a new class... Agent: Clark & Elbing LLP

20080287480 - Therapeutic combination comprising a nmda receptors blocker and a narcotic analgesic substance: The invention relates to a medicament comprising a combination of a substance that blocks both the ion channel associated to NMDA receptors and MAO enzymes and a narcotic analgesic substance, preferably a fixed combination, pharmaceutical compositions thereof, and to the use thereof for the treatment of subjects suffering of various... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080287481 - Process for the preparation of desloratadine polymorph mixtures: The present application provides a process for the preparation of mixture of polymorphic Form I and Form II of desloratadine in any desired ratio.... Agent: Dr. Reddy's Laboratories, Inc.

20080287483 - Polyketides and their synthesis and use: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced... Agent: Dann, Dorfman, Herrell & Skillman

20080287482 - Production of polyketides and other natural products: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the... Agent: Dann, Dorfman, Herrell & Skillman

20080287484 - Neurotrophin antagonist compositions: e

20080287485 - Novel indolizine derivatives, method for preparing same, and therapeutic compositions comprising same:

20080287486 - Prokinetic agent for bowel preparation: The invention provides methods of bowel preparation before a diagnostic, surgical or therapeutic procedure, in particular, bowel preparation before a colonoscopy procedure, using a 5-HT4 receptor agonist as a prokinetic agent.... Agent: Theravance, Inc.

20080287487 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080287489 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective... Agent: Merck And Co., Inc

20080287488 - Use of a sulfonamide compound for improving the pharmacokinetics of a drug: A method for improving the pharmacokinetics of drugs, which are metabolized by cytochrome P450 monooxygenase is disclosed. More specifically it relates to a method for improving the pharmacokinetics of retroviral protease inhibitors and in particular for improving the pharmacokinetics of human immunodeficiency virus (HIV) protease inhibitors. A pharmaceutical composition and... Agent: Philip S. Johnson Johnson & Johnson

20080287490 - Bis-pyridino containing compounds for the use in the treatment of cns pathologies: N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for... Agent: Mcdermott Will & Emery LLP

20080287492 - Alkylpyridyl quinolines as nk3 receptor modulators: n

20080287493 - Arylmethylen substituted n-acyl-y-aminoalcohols:

20080287491 - Tetrahydroquinoline derivative for treating nicotine craving:

20080287494 - Transmucosal treatment methods in patients with mucositis: In accordance with the invention is an fentanyl-containing dosage form designed for transmucosal delivery which includes both an effervescent couple and a pH adjusting substance which can be administered to patients suffering from both pain and mucositis. Also provided is a method of treating pain in a patient having mild... Agent: Cephalon, Inc.

20080287495 - Novel benzo[d][1,3]-dioxol derivatives: The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine... Agent: Edwards Angell Palmer & Dodge LLP

20080287496 - 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels: 1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines substituted in the 4- and/or 7-position of the isoindoline ring and optionally further substituted in the 3-position of the 2,6-dioxopiperidine ring reduce the levels of inflammatory cytokines such as TNFα in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline... Agent: Jones Day

20080287497 - Transdermal methods and systems for the delivery of anti-migraine compounds: Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080287498 - Optically active isomers of ketotifen and therapeutically active metabolites thereof: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.... Agent: Nields & Lemack

20080287499 - N-deacetylthiocolchicine deriatives, their use and pharmaceutical formulations containing them: c

20080287500 - Diastereomers of 4-aryloxy-3-hydroxypiperidines: The present invention relates to essentially pure diastereomers of 4-aryloxy-3-hydroxypiperidines, including purified diastereomers of ifoxetine, methods of purifying said diastereomers, pharmaceutical compositions comprising said diastereomers and methods of treatment utilizing said pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20080287501 - Therapeutic uses of an insulin secretion enhancer: The invention relates to the use of a hypolipidemic agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or delay of the progression to overt diabetes, especially type 2, prevention or reduction of microvascular complications (eg, retinopathy, neurophathy, nephropathy), prevention or reduction of... Agent: Novartis Corporate Intellectual Property

20080287503 - Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases: The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080287502 - Transdermal administration of proton pump inhibitors: A method and composition for the transdermal administration of proton pump inhibitors such as substituted pyridyl methylsulfinyl benzimidazoles, and in particular, omeprazole, lansoprazole, esomeprazole, pantoprazole and raberprazole. The method and composition include the use of a hydroxide-releasing agent as a permeation enhancer to increase the flux of the protein pump... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20080287504 - Cb1 modulator compounds: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis,... Agent: Eli Lilly & Company

20080287505 - Substituted 2-methyl-2-phenoxy-n-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity: The present invention provides novel substituted 2-methyl-2-phenoxy-N-propyl-propionamides and derivatives thereof that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.... Agent: Vance Intellectual Property, PC

20080287506 - Insecticidal n,n-di(heteroarylalkyl) amine derivatives: Certain novel N,N-di(heteroarylalkyl)amine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula (I): wherein Ar Ar1, a, b, c, R, Rd, Re, Rf, Rg, Rh, R′, R3 and Rk are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080287507 - Nicotine containing toiletry waters: A pharmaceutical liquid formulation for delivering nicotine in any form to a subject by transdermal uptake for treating tobacco dependence and similar conditions, said formulation being a toiletry-water. Toiletry-waters encompass aftershaves, eaux-de-parfum, eaux-de-toilette, eaux-de-cologne, toilet-waters and similar products, all in the form of a lotion, a balm or a gel.... Agent: Johnson & Johnson

20080287508 - Altering pharmacokinetics of pirfenidone therapy: The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.... Agent: Marshall, Gerstein & Borun LLP

20080287509 - Pharmaceutical composition for the treatment of bone fracture: Disclosed herein is a composition for the treatment bone fracture comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxyl-benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salts thereof as a medicinally effective ingredient. The composition of the present invention can significantly reduce the volume of bony callus, and increase bony density and strength of bony callus, and decrease the contents... Agent: Casimir Jones, S.c.

20080287510 - Novel compounds as cannabinoid receptor ligands: s

20080287511 - Anthelmintic imidazol-thiazole derivates: The present invention relates to the novel anthelmintic compound tetrahydro-furan-2-carboxylic acid-[3-(2,3,5,6-tetrahydro-imidazo[2,1-b]thiazol-6-yl)-phenyl]-amide and the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, as well as pharmaceutical compositions comprising said novel compound, processes for preparing said compound and compositions, and the use thereof as a medicine, in particular in... Agent: Philip S. Johnson Johnson & Johnson

20080287512 - Plant protection composition including an active compound selected from azoles and a solvent, and useful solvent composition: The present invention relates to a concentrated plant protection composition containing an active compound selected from azoles and preferable triazoles such as tebuconazole. The composition contains at least one solvent. The composition is stable and easy for farmers to use. The present invention further relates to a useful solvent composition... Agent: Hunton & Williams LLP Intellectual Property Department

20080287513 - Topical compositions containing metronidazole: Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, one of which is niacinamide and the other is urea. Related methods are also disclosed.... Agent: Jerry Zhang

20080287514 - Topical compositions containing metronidazole: Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, one of which is niacinamide and the other is hydroxyalkyl urea. Related methods are also disclosed.... Agent: Jerry Zhang

20080287515 - Topical compositions containing metronidazole: Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, one of which is urea and the other is hydroxyalkyl urea. Related methods are also disclosed.... Agent: Jerry Zhang

20080287516 - Phenyl-substituted pyrrolidones: The present invention relates to phenyl-substituted pyrrolidones and compounds related to phenyl-substituted pyrrolidones. One use of these compounds is for the inhibition of viruses, e.g., HIV. The invention further relates to methods of malting these compounds, methods of identifying the efficacy of these compounds, and methods of using these compounds... Agent: Genomics Institute Of The Novartis Research Foundation

20080287517 - Pyrazole derivatives as cb1 modulators: wherein R1 represents a group R5O— in which R5 represents a C3-7alkyl group substituted by one or more fluoro or R5 represents a C3-7alkylsulphonyl group which is optionally substituted by one or more fluoro; R2 represents a C1-4alkyl group, hydroxy, fluoro, chloro or cyano wherein each R2 is independently selected... Agent: Morgan Lewis & Bockius LLP

20080287518 - Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2): Use of a benzoyl derivative of 3-aminocarbazole to produce a drug for the preventive or therapeutic treatment of a disorder selected form the group comprising inflammatory processes, pain, fever, tumours, Alzheimer's disease and atherosclerosis. Method for the preventive or therapeutic treatment of a disorder selected from the group comprising inflammatory... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080287519 - Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide: The invention encompasses amorphous eletriptan hydrobromide, processes for preparing it and pharmaceutical compositions of it. The invention also relates to processes for preparing other forms of eletriptan hydrobromide such as Form α and Form β.... Agent: Kenyon & Kenyon LLP

20080287520 - Use of melatonin in preventing postoperative complications: The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture... Agent: Fulbright & Jaworski L.L.P.

20080287521 - Crystalline forms of [r-(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl- ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1): Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR,... Agent: Pfizer Inc.

20080287522 - Benzylated pde4 inhibitors: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either... Agent: Seed Intellectual Property Law Group PLLC

20080287523 - Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to pyrrolidin-3-yl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20080287524 - Method of purifying a surfactant by ultrafiltration: A method of purifying a surfactant for use in a pharmaceutical formulation, which comprises mixing the surfactant with a solvent and bringing said mixture into contact with a semi-permeable membrane so as to allow impurities present in the surfactant and having a molecular weight lower than the molecular weight cut-off... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20080287525 - Pharmaceuticals for treating or preventing oral diseases: The present invention discloses Mulberrofuran G, a method of extracting Mulberrofuran G, as well as various uses of Mulberrofuran G in manufacturing antibacterial medicaments or oral care products or for other antibacterial uses.... Agent: Baker & Mckenzie LLP

20080287526 - Pharmaceuticals for treating or preventing oral diseases: The present invention discloses a new compound of formula (I), a method of extracting the new compound, as well as various uses of the new compound in manufacturing antibacterial medicaments or oral care products or for other antibacterial uses.... Agent: Baker & Mckenzie LLP

20080287527 - Pharmaceuticals for treating or preventing oral diseases: The present invention discloses hydroxy-morusin, a method of extracting hydroxy-morusin, as well as various uses in manufacturing antibacterial medicaments or oral care products or for other antibacterial uses.... Agent: Baker & Mckenzie LLP

20080287528 - Therapeutic methods and compositions involving isoflavones: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA... Agent: Sughrue Mion, PLLC

20080287529 - Crystal structures of sglt2 inhibitors and processes for preparing same: e

20080287531 - Preventive and/or therapeutic agent for sleeping disorder:

20080287530 - Tripolide lactone ring derivatives as immunomodulators and anticancer agents: Disclosed are compounds based on lactone ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.... Agent: Perkins Coie LLP

20080287532 - Oxacyclopentene-2 derivatives: The present invention relates to oxacyclopentene-2 derivatives as compounds possessing antiinflammatory, neuroprotective, immunomodulatory and cardiovascular activities in mammals.... Agent: Alpharx Inc.

20080287533 - Ascorbic acid - natural sugar lactone esters for comprehensive skin & scalp care: This invention relates to esters of ascorbic acid with natural sugar lactones [formula (I)], which are useful for the treatment of skin condition, including age spots, acne, loss of cellular antioxidants, collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles including fine lines, oxidation, damage from radiation,... Agent: Shyam K. Gupta Bioderm Research

20080287534 - Method for controlling insect pests on plants: Disclosed is a method for protecting a plant planted in a growing medium from foliar insect pests comprising applying an insecticidally effective amount of a mixture comprising methomyl and oxamyl to the growing medium.... Agent: Birch, Linda D. E.i. Du Pont De Nemours And Company

20080287535 - Pesticidal diazene oxide carboxylates: Y is phenyl; benzyl; thiazolyl; thienyl; pyridyl; or tetrahydrofuranyl, the aromatic ring of each substituent being optionally substituted with one or more of halogen, C1-C6 branched or straight-chain alkyl, or C1-C6 branched or straight-chain haloalkyl; use of the compounds as pesticides and pesticidal compositions comprising the compounds.... Agent: Chemtura Corporation

20080287536 - Skin and hair restoration by natural amino acid and peptide crown complexes: i

20080287538 - Antimicrobial compositions and methods: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including, in particular, a fatty alcohol ester of a hydroxycarboxylic acid, alkoxylated derivatives thereof, or combinations thereof. The compositions can also include an enhancer component, a surfactant component, a hydrophobic component, and/or a hydrophilic component.... Agent: 3m Innovative Properties Company

20080287537 - Composition, particularly a cosmetic composition, comprising ((dialkylamino)alkoxy) ethanol ester: t

20080287539 - Use of carnitines for the prevention and/or treatment of disorders caused by the andropause: L-carnitine, propionyl L-carnitine and/or acetyl L-carnitine are used to prevent or treat disorders of male andropause caused by ageing or by chemical or surgical castration.... Agent: Nixon & Vanderhye, PC

20080287540 - Lip care compositions: A lip care composition is provided which includes at least 40% petrolatum, at least 5% glycerin, and 1 to 20% of a C3 (alkyl or hydroxyalkyl) alcohol ester of isostearic acid, wherein the glycerin and the isostearic acid ester are present in a weight ratio ranging from 5:1 to 1:1.... Agent: Unilever Patent Group

20080287541 - Kit for treatment of cancer: The present invention relates to a kit for the treatment of cancer comprising (a) a container for containing a first compound (i) or a precursor thereof, said first compound or precursor being a compound that oxidizes glutathione (GSH); (b) a container for containing a second compound (ii) or a precursor... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080287542 - Novel isovaleramide forms, compositions thereof, and related methods of use: The invention provides novel isovaleramide forms. These forms include isovaleramide co-crystals, and solvates, hydrates, co-crystals, and polymorphs thereof. The invention also provides novel compositions comprising these novel forms and one or more suitable carriers. The invention also provides related methods of treatment or prevention. Compositions and methods of the invention... Agent: Philip S. Johnson Johnson & Johnson

20080287543 - Pharmaceutical composition comprising 5-methyl-2 (2'-chloro-6'-fluoroanillino) phen ylacetic acid: The invention relates to a composition for the treatment of a cyclooxygenase-2-mediated disorder or condition comprising 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof suitable for parenteral administration, and to a method for the treatment of a cyclooxygenase-2-mediated disorder or condition in a human or animal... Agent: Novartis Corporate Intellectual Property

20080287544 - Method for screening substance by measuring ppar delta activating effect and agent: The present invention provides an agent containing a compound having an effect activating PPARδ, which is a peroxisome proliferator activated receptor, and having effects which enhances nonshivering thermogenesis (nST), specifically enhances uncoupling respiration in mitochondria of cells in an adipose tissue or the like, or proton leak in inner membranes... Agent: Sughrue Mion, PLLC

20080287546 - Quorum sensing modulators: Compounds described herein are useful in modulating bacterial quorum sensing.... Agent: Miller Canfield Paddock And Stone PLC

20080287545 - Use of peptide compounds for the prophylaxis and treatment of chronic headache: The present invention is directed to the use of a class of peptide compounds for the prophylaxis and treatment of chronic headache, particularly migraines.... Agent: Harness, Dickey, & Pierce, P.l.c

20080287547 - Glycine transport inhibitors: The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080287548 - Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase: The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as neurodegenerative diseases and heart failure.... Agent: Cozen O'connor, P.C.

20080287549 - Methods and materials for controlling rodent populations: The present invention relates to the use of compositions comprising clomiphene isomers for controlling rodent populations. The clomiphene isomers lower testosterone and/or suppress appetite in the rodent population.... Agent: Howrey LLP - Dc

20080287550 - Sertraline hydrochloride form ii and methods for the preparation thereof: The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized... Agent: Steven J. Lee Kenyon & Kenyon

20080287551 - Carotenoid formulation: The present invention discloses the use of a lycopene coated with a water non-soluble thin film comprising amphiphilic protein polymer for coloring with red color, foods, pharmaceuticals or cosmetics having fat and/or oil contents higher than 5%. The invention further discloses a process for the preparation of stable lycopene formulation... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080287553 - Pharmaceutical compositions comprising peranhydrocyclodextrin: The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.... Agent: Novartis Corporate Intellectual Property

20080287552 - Process for obtaining an active ingredient for enhancing cutaneous mechanical strength, active ingredient and compositions: e

20080280813 - Complex drug delivery composition and method for treating cancer: The present invention relates to compositions and methods for producing a complex drug delivery system which specifically targets cancer cells, has an increase in cellular uptake, is cytotoxic, and suppresses antiapoptotic cellular defenses.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080280811 - Compositions and methods for treating vascular permeability: The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.... Agent: Clark & Elbing LLP

20080280812 - Human immunosuppressive protein: A method for purifying an immunosuppressant protein (HISP) has the steps of obtaining supernatant from hNT cells; exposing the supernatant to preparative polyacrylamide gel electrophoresis to produce 20 isoelectric fractions, including active isoelectric fraction #10; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting... Agent: The Luther Law Firm, PLC

20080280810 - Peptides having affinity for body surfaces: Peptides having affinity for a body surface are provided. The peptides comprise a body surface-binding peptide block and at least one charged, terminal peptide block. These peptides have enhanced affinity for body surfaces and deposit more rapidly onto body surfaces than peptides lacking the charged terminal groups. The peptides are... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080280815 - Lowering serum lipids: The present invention relates to a method for lowering serum lipids, eg. triglycerides and/or cholesterol in a subject comprising administering a GLP-1 agonist to said subject.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080280816 - Methods and pharmaceutical compositions for healing wounds: A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected... Agent: Fulbright & Jaworski, LLP

20080280817 - Modified amino acid for the inhibition of platelet aggregation: A method of inhibiting blood platelet aggregation in a mammal is provided. The method comprises the administration of a platelet aggregation inhibiting amount of a modified amino acid or pharmaceutically acceptable salt thereof.... Agent: Novartis Corporate Intellectual Property

20080280814 - Pharmaceutical compositions containing insulin and insulinotropic peptide: Pharmaceutical composition for parenteral administration comprising insulin peptide an insulinotropic peptide and a ligand for the Hisb10 anion site.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080280818 - Glycosylation of peptides via o-linked glycosylation sequences: The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries... Agent: Morgan, Lewis & Bockius LLP (sf)

20080280819 - Methods for promoting hair growth: This disclosure reveals that cyclic corticotrophin releasing factor (CRF) antagonist peptides (such as astressin B, its functional fragments, and their derivatives) induce hair growth and prevent hair loss in vivo. This important discovery enables, for instance, methods of promoting hair growth, and methods of treating hair loss (such as the... Agent: Klarquist Sparkman, LLP

20080280820 - Novel peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080280821 - recombinant protein having an anti-cancer effect, its encoding gene and uses thereof: The present invention discloses a recombinant protein having an anti-cancer effect, its encoding gene and uses thereof. The recombinant protein having an anti-cancer effect provided by the present invention is one selected from the group consisting of: 1) a protein having the amino acid sequence of SEQ ID No:2 shown... Agent: Fish & Richardson PC

20080280831 - Chimeric proteins with phosphatidylserine binding domains: Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidylserine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn... Agent: Dunlap Codding, P.C.

20080280824 - Compositions and methods for treatment of cancer or neurodegenerative disease with peptide based microtubule stabilizers or inhibitors: Small molecular weight molecules are provided including, but not limited to, peptides, peptide analogs and peptide mimetics that can interact with microtubules to promote their assembly or prevent their disassembly and can interrupt mitosis, prevent cell division, and trigger apoptosis. methods for the prevention or treatment of neoplastic disease in... Agent: Woodcock Washburn LLP

20080280828 - Compositions comprising igbpma and uses thereof: The present invention relates generally to methods and materials for treating conditions associated with IgE activation in humans and animals, and to agents capable of modulating the activation. The agents of the invention comprise or are related to IGBPMA polypeptides from ticks.... Agent: Michael Best & Friedrich LLP

20080280830 - Fusion protein comprising fk506 binding protein and method of making and using the same: Disclosed is a fusion protein containing a FK506 binding protein and a cell-transducing domain. Also, disclosed is a method of making the fusion protein and use of the fusion protein in a pharmaceutical or cosmetic composition. The cell-transducing domain is, for example, a PEP-1.... Agent: Knobbe Martens Olson & Bear LLP

20080280827 - Inhibitor of tgf-beta activation reaction: The present invention aims to provide a substance(s), especially a peptide(s) capable of inhibiting the TGF-β activation reaction. The present invention provides a peptide consisting of 11 to 50 amino acid residues, which comprises an amino acid sequence Gln-Ile-Leu-Ser-X1-X2-X3-X4-Ala-Ser-Pro (SEQ ID NO: 1) wherein each of X1 to X4 independently... Agent: Greenblum & Bernstein, P.L.C

20080280826 - Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway: Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. These molecules can be delivered alone or in combination with one or... Agent: Fenwick & West LLP

20080280829 - Methods of treatment and prevention of metabolic bone diseases and disorders: The present invention provides compostions and methods useful for treating and preventing metabolic bone diseases and disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing metabolic bone diseases and disorders such as, for example osteoporosis, osteopenia and osteopenia related diseases and abnormal bone marrow.... Agent: David S. Resnick

20080280832 - Novel fsh glycosylation variant d3n: FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080280822 - Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer: A novel gene (designated 161P5C5) and its encoded protein, and variants thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table 1. Consequently, 161P5C5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P5C5 gene... Agent: Agensys C/o Morrison & Foerster LLP

20080280825 - Protective complement proteins and age-related macular degenration: Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including... Agent: Townsend And Townsend And Crew, LLP

20080280823 - Treatment of non-alcoholic steatotic hepatitis (nash): The present invention relates to a method for treating nonalcoholic steatotic hepatitis (NASH) in a subject by administering an effective amount of a lipoprotein lipase (LPL) therapeutic to the subject. The LPL therapeutic is advantageously a S447X protein or a derivative or variant thereof, or a nucleic acid encoding such... Agent: Morgan & Finnegan, L.L.P.

20080280833 - Therapeutic peptides derived from urokinase plasminogen activator receptor: The present invention relates to a chemotactically active epitope derivable from the urokinase receptor, a mutated peptide that acts as an inhibitor of chemotaxis, and their therapeutic use.... Agent: Bozicevic, Field & Francis LLP

20080280834 - Compounds and methods for inhibiting apoptosis: The invention provides compounds, compositions, and methods for inhibiting apoptosis and for the treatment of conditions related thereto.... Agent: Leydig Voit & Mayer, Ltd

20080280835 - Novel use of peptide compounds for treating muscle pain: The present invention is directed to the use of a class of peptide compounds for treating non-inflammatory musculoskeletal pain or/and non-inflammatory osteoarthritic pain.... Agent: Millen, White, Zelano & Branigan, P.C.

20080280836 - Anti-hypercholesterolemic biaryl azetidinone compounds: and the pharmaceutically acceptable salts thereof, wherein R12 is an alkyl, alkeny or alkynyl group mono- or poly-substituted with —OH, —COOH or a combination of —OH and —COOH, and R9 contains an alkyl, alkeny or alkynyl group substituted with a heterocyclic ring, amino or sulfonyl. The compounds are useful for... Agent: Merck And Co., Inc

20080280837 - Biologically active compounds with anti-angiogenic properties: A method for inhibiting angiogenesis in a subject comprising administering to the subject at least one compound of General Formula (I), wherein the ring or any chiral center(s) may be of any configuration; Z is sulphur, oxygen, CH2, C(O), C(O)HN, NH, NRA or hydrogen, in the case where Z is... Agent: Morrison & Foerster LLP

20080280838 - Composition containing ginsenoside f1 and egcg for preventing skin damage: The present invention relates to a skin-care composition containing ginsenoside F1 and EGCG. More particularly, the present invention relates to an inhibitor of UV-induced apoptosis in epidermal cells showing an excellent skin-care effect by the synergistic interaction of the said ginsenoside F1 and EGCG even at low concentrations, and to... Agent: Sughrue Mion, PLLC

20080280839 - Anti-cancer activity of androsace umbellata merr. extract and contained triterpene saponin: The present invention relates to an Androsace umbellata Merr. extract having anticancer activity and a triterpene saponin compound isolated therefrom, more particularly to an Androsace umbellata (Lour.) Merr. extract, triterpene saponin compounds isolated therefrom, saxifragifolin B and saxifragifolin D, which inhibit the growth of cancer cells and induce apoptosis of... Agent: Frommer Lawrence & Haug

20080280840 - Meloxicam for the treatment of respiratory diseases in pigs: A method of treating or preventing a respiratory disease in a pig, the method comprising administering to the pig in need thereof an effective amount of meloxicam or a pharmaceutically acceptable salt thereof.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080280841 - Amorphous telithromycin compound: The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.... Agent: Sandoz Inc

20080280842 - Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection: The present invention provides fluorinated pyrrolo[2,3,d]pyrimidine nucleoside compounds which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B... Agent: Merck And Co., Inc

20080280846 - 2', 3'-dideoxynucleoside analogues for the treatment or prevention of flaviviridae infections: A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a β-L- or β-D-2′,3′-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable... Agent: Merchant & Gould PC

20080280845 - Compositions and their uses directed to ptpru: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also... Agent: Knobbe, Martens, Olson & Bear, LLP

20080280844 - Methods and compositions for the diagnosis and treatment of ewing's sarcoma: The present invention relates to methods and compositions for the detection and treatment of Ewing's sarcoma. In particular, the methods of detection relate to measuring in Ewing's sarcoma cells the expression of the NKX2.2 gene, as well as targets genes downstream of NKX2.2. The compositions and method of treatment for... Agent: Foley & Lardner LLP

20080280843 - Methods and kits for linking polymorphic sequences to expanded repeat mutations: Methods and kits are provided for determining which single nucleotide polymorphism (“SNP”) variant of an allele of a heterozygous patient is on the same mRNA transcript as a disease-causing mutation that is at a remote region of the gene's mRNA comprising a) an allele-specific reverse transcription reaction using an allele-specific... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080280847 - Pit-1 and vascular calcification: The present invention relates to methods and compositions comprising small interfering RNAs (siRNAs) to identify nucleotides encoding proteins involved in the co-transport of inorganic phosphate in vascular tissues. Specifically, it relates to the identification of Pit-1 and Pit-2 as key proteins involved in vascular calcification, the deposition of calcium phosphate,... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080280848 - Structures of active guide rna molecules and method of selection: The present invention relates to methods and compositions for modulating RNA silencing efficiency by providing selective RISC (RNA-induced silencing complex) formation. The present invention also relates to methods for identifying nucleic acids and/or determining their structures.... Agent: Nixon Peabody, LLP

20080280849 - Synergic combinations comprising a quinoline compound and other hiv infection therapeutic agents: The invention relates to a combination comprising a quinoline compound or its sail, according to general formula (I) and at least one HIV infection therapeutic agent selected from the group consisting of entry inhibitors, reverse-transcriptase inhibitors, strand-transfer inhibitors, protease inhibitors, and maturation inhibitors. Said combination has therapeutic synergy in the... Agent: Stites & Harbison PLLC

20080280850 - Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus: A method and composition for treating a host infected with flavivirus, pestivirus or hepacivirus comprising administering an effective flavivirus, pestivirus or hepacivirus treatment amount of a described base-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.... Agent: Jones Day

20080280851 - Oral dosage forms of gemcitabine derivatives: The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2′,2′-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in... Agent: Fitzpatrick Cella Harper & Scinto

20080280852 - Composition containing fermentable polysaccharides: The present invention relates to a composition to a nutritional composition comprising 0.1 to 15 gram fermentable e partially hydrolysed gum having a degree of polymerisation between 10 and 300 per 100 gram dry weight of the composition and 0.1 to 15 gram fermentable, indigestible polysaccharide other than a hydrolysed... Agent: Foley And Lardner LLP Suite 500

20080280853 - Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same: Compositions for relief, treatment, or prevention of a condition of dry eye comprise alginate, at least a polyol, and a pharmaceutically acceptable carrier, wherein the compositions have pH in the range from about 5 to about 7.5. In some embodiment, the compositions can further include a chelating agent, a buffering... Agent: Bausch & Lomb Incorporated

20080280854 - Preventing or reducing oxidative stress or oxidative cell injury: A water-soluble cellulose derivative is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for regulating Stearoyl-CoA Desaturase-1 gene expression and/or ATPF1 gene expression in non-adipose tissues of the animal.... Agent: The Dow Chemical Company

20080280855 - Process for the production of intermediates for the preparation of tricyclic benzimidazoles: w

20080280856 - Fibroblast activation protein inhibitor compounds and methods: Amino terminus-blocked peptide boronate compounds of Formulas I and II are useful for inhibiting Fibroblast Activation Protein (FAP) and other proteases, and for treating disorders mediated by FAP. Methods of using the amino terminus blocked peptide boronate compounds, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro,... Agent: Genentech, Inc.

20080280857 - Cgrp receptor antagonists: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.... Agent: Merck And Co., Inc

20080280858 - Method of creating crystalline substances: Process for preparing a cocrystal of an active substance and a cocrystal former, the process involving precipitating the active substance and the cocrystal former together from solution or suspension, in the presence of a supercritical or near-critical fluid, in particular using a GAS, SAS, SEDS or SAS-EM process. The invention... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080280859 - Gemini vitamin d3 compounds and methods of use thereof: The invention provides Gemini vitamin D3 compounds, methods for using the compounds to treat vitamin D3 associated states and pharmaceutical compositions containing the compounds.... Agent: Edwards Angell Palmer & Dodge LLP

20080280860 - Use of vitamin d compounds to treat endometriosis: The use of vitamin D compounds in the treatment or prevention of endometriosis, methods for the treatment or prevention of endometriosis by administering a vitamin D compound, and compounds for use therein.... Agent: Edwards Angell Palmer & Dodge LLP

20080280861 - Method of female contraception and a kit for use therein: The invention is concerned with a method of contraception in a female mammal of childbearing capability. The method has two alternating phases—a preservation phase and a shedding phase—and has at least two sequences of (a) a preservation phase of 3-12 months involving continuous oral administration to the female of dosage... Agent: The Webb Law Firm, P.C.

20080280863 - Compositions for the treatment of inflammatory disorders: The invention features methods and compositions for the treatment of immunoinflammatory disorders.... Agent: Clark & Elbing LLP

20080280862 - Methods, compositions, and kits for the treatment of pain: The invention features methods, compositions, and kits for the treatment of pain.... Agent: Clark & Elbing LLP

20080280864 - Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity: Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080280865 - Water-in-oil type emulsified composition: Water-in-oil type emulsified compositions with a high silicone oil content which are excellent in emulsification stability and whose sticky feeling has been improved may be obtained by incorporating a specific (A) N-long chain acyl neutral amino acid ester, (B) a silicone oil, and (C) water therein.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080280866 - Method of treating or sepsis: Provided is a method of treating trauma or sepsis comprising: administering an effective amount of one or both of a SOC channel-selective inhibitor or a SphK inhibitor to an animal at risk of inflammation-mediated organ damage from trauma or sepsis.... Agent: MoserIPLaw Group

20080280867 - Combination therapy with parp inhibitors: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with temozolomide (TMZ).... Agent: Paul D. Yasger Abbott Laboratories

20080280870 - Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists: Substituted 2-(azetidin-2-on-1-yl)alkoxyalkylalkanoic acids and 2-(azetidin-2-on-1-yl)arylalkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using the described compounds, and pharmaceutical compositions thereof, to treat disease states responsive to antagonism of one or more vasopressin receptors are also described.... Agent: Barnes & Thornburg LLP

20080280869 - Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a... Agent: Hoffmann & Baron, LLP

20080280871 - 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylin ositol 3 kinase enzymes (pi13) for treatment of inflammatory diseases: in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.... Agent: Novartis Corporate Intellectual Property

20080280877 - Azetidines:

20080280872 - Benzamide derivatives and their use as glucokinase activating agents: Compounds of Formula (I): wherein: R1 is methoxymethyl; R2 is selected from —C(O)NR4R5, —SO2NR4R5, —S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl,... Agent: Morgan Lewis & Bockius LLP

20080280873 - Biaryl substituted pyrazinones as sodium channel blockers: Biaryl substituted pyrazinone compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by,... Agent: Merck And Co., Inc

20080280875 - Fused phenyl amido heterocyclic compounds: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase,... Agent: Pfizer Inc.

20080280876 - Novel oxadiazole compounds: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.... Agent: Abbott Bioresearch

20080280874 - Phenoxy benzamide compounds with utility in the treatment of type 2 diabetes and obesity: wherein: R1 is methoxymethyl; R2 is selected from —C(O)NR4R5, —SO2NR4R5, —S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano;... Agent: Morgan Lewis & Bockius LLP

20080280868 - Pyridine derivatives and their use as cb2 receptor modulators: e

20080280878 - Methods and compositions for treating chronic lymphocytic leukemia: Novel method of treating chronic lymphocytic leukemia by the administering of HSP90 inhibitors, particularly ansamycins, more particularly I 7-allylamino-I 7-demethoxygetdanarnycin (17-AAG).... Agent: Wilson Sonsini Goodrich & Rosati

20080280879 - Substituted heterocyclic derivatives and their pharmaceutical use and compositions: Compounds of the general Formula I, wherein X1, X2, X3, X4, X5, X6, X7, R1, R2, R4, R5, R6, R7, R8, R9, R10, Y1, n, m, p and q are defined as above, their preparation and their use as antimicrobial agents.... Agent: Pfizer Inc Steve T. Zelson

20080280880 - Staurosporine derivatives for use in alveolar rhabdomyosarcoma: This invention relates to staurosporine derivatives are effective when used in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a disease associated with a PAX/FKHR translocation including a PAX3/FKHR translocation and a PAX7/FKHR translocation, more especially a solid tumor disease such as... Agent: Novartis Corporate Intellectual Property

20080280881 - Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication: a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C1-10alkanediyl; R1 is Ar1 or a monocyclic or bicyclic heterocycle Q is R7, pyrrolidinyl substituted with R7, piperidinyl substituted with R7 or homopiperidinyl substituted with R7; one... Agent: Philip S. Johnson Johnson & Johnson

20080280882 - Novel substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: p

20080280883 - Muscarinic receptor antagonists: This present invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed... Agent: Ranbaxy Inc.

20080280885 - Methods for treating anxiety related disorders: The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. In one treatment method, methods of, and compositions for, modulating the expression of certain GABAA receptor subunits are used to... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080280884 - Mixed solvate of olanzapine, method for preparing it and method for preparing form i of olanzapine therefrom: Said mixed solvate is a solvate of olanzapine/water/tetrahydrofuran in the proportion 1:1:1/2 (I). The method for preparing said solvate comprises treating a crude anhydrous olanzapine with a mixture of tetrahydrofuran/water. The method for preparing Form I of olanzapine includes desolvating the mixed solvate of formula I, by means of drying,... Agent: Wolf Block Schorr And Solis-cohen LLP

20080280886 - Substituted ureas: Disclosed herein are urea-based 5-HT receptor modulators, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of 5-HT receptor-mediated disorders.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080280887 - Selected cgrp-antagonists, processes for preparing them and their use as pharmaceutical compositions: The invention relates to CGRP-antagonists of general formula (I), wherein R1, R2, R3, R4 and R5 are defined in claim 1, to the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures salts and salt hydrates thereof, in particular to 10 salts thereof, which are physiologically compatible with acids or inorganic or organic... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080280888 - Antibiotics derivatives: e

20080280890 - Hydroxylamine compounds and methods of their use: The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related... Agent: Woodcock Washburn LLP

20080280889 - Inhibitors of akt activity: The present invention is directed to compounds which contain substituted pyridazines and pyrimidines moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration (if the compounds of the... Agent: Merck And Co., Inc

20080280891 - Anti-cancer agents and uses thereof: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring... Agent: Pepper Hamilton LLP

20080280892 - Compounds: Tricyclic nitrogen containing compounds and their use as antibacterials.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080280894 - Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080280893 - Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080280895 - 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension: The application relates to novel alkanamides of the general formula (I) where X is —CH2— or >CH—OH; (A) R1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R2 is C1-C6-alkyl or C3-C6-cydoalkyl; R3 are each independently H, C1-C6-alkyl, C1-6-alkoxycarbonyl... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080280897 - Aerosol formulation for inhalation: The present invention relates to a propellant-free aerosol formulation which contains one or more compounds of general formula 1.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080280896 - Dipyrrole compounds, compositions, and methods for treating cancer or viral diseases: The present invention relates to novel Dipyrrole Compounds, compositions comprising a Dipyrrole Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Dipyrrole Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or... Agent: Wilmerhale/boston

20080280898 - Spiro-piperidine derivatives: e

20080280900 - Bicyclic pyrimidine derivatives as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing thienopyrimidine or oxoquinazoline derivatives are disclosed of the general formula (1) or formula (2) where X is a linker and Y is an... Agent: Morrison & Foerster LLP

20080280899 - Inhibitors of akt activity: The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.... Agent: Merck And Co., Inc

20080280903 - Apoptosis inhibitors: The present invention provides compounds that act as selective agents to protect against unintentional cell death or tissue damage and can relieve side effects of cancer treatment such as, for example, oral mucositis, hair loss, diarrhea due to damage to the gastrointestinal epithelium, and myelosuppression. In addition, these compounds can... Agent: Schwegman, Lundberg & Woessner, P.A.

20080280902 - Inhibitors of checkpoint kinases: The instant invention provides for compounds which comprise substituted quinolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20080280904 - N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors: Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080280901 - Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.... Agent: Sughrue Mion, PLLC

20080280905 - Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080280906 - Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders: e

20080280907 - Triazolophthalazines:

20080280908 - Naphthyl(ethyl) acetamides: This disclosure relates to novel melatonin analogues or naphthyl(ethyl)acetamides, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual... Agent: Fish & Richardson P.C.

20080280911 - Cinnoline compounds as inhibitors of phosphodiesterase type iv (pde4): There are provided according to the invention novel compounds of formula (I)... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080280909 - New phenylalanine derivatives: e

20080280910 - Phthalazinone derivatives:

20080280912 - Novel diazabicycylic aryl derivatives and their medical use: This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20080280913 - Tetrahydrotriazolopyrazine derivatives and uses thereof: This invention relates to novel substituted tetrahydrotriazolopyrazines and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an enzyme inhibitor... Agent: Woodcock Washburn LLP

20080280914 - Intravenous formulations of pde inhibitors: The invention relates to a novel pharmaceutical dosage form of PDE 5 inhibitors for intravenous administration and the use thereof for the treatment of diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20080280916 - Pyridazine derivatives and their use as therapeutic agents: e

20080280917 - Nitrogen-containing heterocyclyl ketones and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20080280918 - Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors: The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives of Formula (I) and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention or suppression of pathological conditions, diseases and disorders known to be susceptible of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080280915 - Insecticidal n-substituted (heteroaryl)alkyl sulfilimines: N-Substituted (heteroaryl)alkyl sulfilimines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20080280919 - Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors: S

20080280920 - Plasminogen activator inhibitor-1 inhibitors: Inhibitors of plasminogen activator inhibitor-1 (PAI-I) are provided, which may also act as anti cancer agents, of formulae (I-V).... Agent: Frommer Lawrence & Haug

20080280921 - Amorphous aripiprazole and process for the preparation thereof: Morphologically stabilized amorphous aripiprazole and process for preparing the same.... Agent: Swanson & Bratschun, L.L.C.

20080280922 - Intermittent dosing regimen for overweight and obese subjects: The present invention concerns an intermittent dosing regimen for the treatment of obesity or the reduction of body weight wherein a pharmaceutical composition containing an apoB secretion/MTP inhibitor is administered to a subject in need thereof for a period of time, then withheld for a period of time, and again... Agent: Philip S. Johnson Johnson & Johnson

20080280923 - 1-benzylindole-2-carboxamide derivatives: The present invention relates to i-benzylindole-2-carboxamide derivatives of formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 1-benzylindole-2-carboxamide derivatives and to their use in therapy, particularly for the treatment of obesity or nicotine dependence.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080280924 - Pyridine and pyrimidine derivatives as mglur2 antagonists: e

20080280925 - Amines as small molecule inhibitors: The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as... Agent: Keown & Zucchero, LLP

20080280926 - Phosphodiesterase inhibitors: The present invention relates to purine derivatives, which can be used as selective phosphodiesterase (PDE) type IV inhibitors. Compounds disclosed herein can be useful in the treatment of asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic... Agent: Ranbaxy Inc.

20080280927 - 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use: This invention relates to novel 3-(dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of cyclic guanosine... Agent: Edwards Angell Palmer & Dodge LLP

20080280928 - Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as crf antagonists: i

20080280929 - Antifungal wallboards and building materials and methods for the production thereof: The present invention relates to, inter alia, methods for the treatment of wallboards and the treated wallboards. In particular, the invention relates to the treatment of wallboards with a fungicidally effective amount of a strobilurin or strobilurin-type fungicide. In a particular embodiment the fungicide is azoxystrobin. The invention also provides... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080280931 - Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor: e

20080280930 - Pyrimidinone compounds and preparation and use thereof: Disclosed are pyrimidinone compounds having formula (I), a preparation and use thereof. The compounds are inhibitors of HMG-CoA reductase, and therefore have antivirus activities and are useful for preventing and treating cardiovascular and cerebrovascular disorders, senile dementia, diabetes mellitus, osteoporosis and tumors, and enhancing immune functions in a subject, and... Agent: Knobbe Martens Olson & Bear LLP

20080280932 - Compositions and methods for treating vascular, autoimmune, and inflammatory diseases: The disclosure provides methods and compositions for the treatment of vascular, autoimmune and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.... Agent: Dechert LLP

20080280933 - Benzimidazolyl compounds: e

20080280934 - Method of preparing porphyrin derivatives, porphyrin derivatives, uses thereof and pharmaceutical compositions: Method of preparing a porphyrin derivative starting from a meso-substituted porphyrin compound. According to the invention, the meso-substituted porphyrin compound used is a meso-(2′-cyanovinyl)-substituted porphyrin compound, wherein said meso-(2′-cyanovinyl)-substituted porphyrin compound, in a form in which its porphyrin ring is complexed with a bivalent metal ion is converted, in the... Agent: Mayer Brown LLP

20080280935 - Process to prepare camptothecin derivatives: A process is provided for the preparation of camptothecin derivatives, such as irinotecan, in a one-pot operation.... Agent: Klarquist Sparkman, LLP

20080280936 - Morphinan compounds: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor... Agent: Fish & Richardson P.C.

20080280937 - Ligand conjugates of vinca alkaloids, analogs, and derivatives: Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of cytotoxic drugs and vitamin receptor binding ligands. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers.... Agent: Barnes & Thornburg LLP

20080280938 - Screening method: The present invention provides a medicament for preventing/treating cancer, comprising a tacrine compound, or a compound promoting the binding between the tacrine compound and a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1.... Agent: Sughrue Mion, PLLC

20080280939 - Combination of organic compounds: The invention relates to a pharmaceutical combinations comprising an AT1 receptor blocker or pharmaceutically acceptable salts thereof and a mTOR inhibiting agent, e.g. rapamycin or a rapamycin derivative, optionally in the presence of a pharmaceutically acceptable carrier.... Agent: Novartis Corporate Intellectual Property

20080280940 - Rapamycin derivative or an impdh inhibitor for treating polycystic kidney disease: A method for treating polycystic kidney disease, comprising administering to a subject in need thereof a therapeutical effective amount of an inosine-5′-monophosphate dehydrogenase inhibitor or a rapamycin derivative.... Agent: Novartis Corporate Intellectual Property

20080280941 - 8-phenoxy-gamma carboline derivatives: Compounds of Formula I and corresponding pharmaceutical compositions are disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20080280943 - Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders: Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption... Agent: Edwards Angell Palmer & Dodge LLP

20080280942 - Tetrahydro-beta-carbolin-sulfonamide derivatives as 5-ht6 ligands: The present invention relates to new tetrahydro-β-carbolin-sulfonamide derivatives of general formula (I), optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding physiologically... Agent: Knobbe Martens Olson & Bear LLP

20080280945 - Crystalline forms of an hiv integrase inhibitor: Crystalline forms of a hexahydro-diazocinonaphthyridine trione compound are disclosed. The compound and its crystalline forms thereof are HIV integrase inhibitors useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset or progression of AIDS.... Agent: Merck And Co., Inc

20080280944 - Imidazo[1,2-a]pyridine derivatives for the treatment of silent gastro-esophageal reflux: The present invention relates to a new method of treatment of sleep disturbance due to silent gastro-esophageal reflux. In particular, the present invention relates to the use of certain imidazo (1,2-a)pyridines derivatives (I) in said treatment.... Agent: White & Case LLP Patent Department

20080280947 - Anti-insomnia compositions and methods: Compositions of zolpidem, and methods for their manufacture and use for treating insomnia. The compositions are formulated as oral sprays for transmucosal absorption of zolpidem. The methods of treatment in some cases involve night-time dosing administration to achieve therapeutic zolpidem blood levels within 20 minutes or less, tapering off to... Agent: Dickstein Shapiro LLP

20080280946 - Azaindole-derivatives as factor xa inhibitors: wherein R0, R1, R2, R3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080280948 - Modulators of amyloid beta: e

20080280949 - Oxopyridyl quinoline amides as nk3 receptor modulators: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080280950 - Hydantoin derivatives useful as metalloproteinase inhibitors: Formula (I) wherein R1 is a (2-4C)alkyl and is substituted by two or more fluorine groups and R2 is methyl or ethyl, or a pharmaceutically acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by metalloproteinase... Agent: Morgan Lewis & Bockius LLP

20080280951 - Salt il: The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-hydroxyphenyl}acetamide furoate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy.... Agent: Fish & Richardson P.C.

20080280953 - Agents used for the treatment of seeds: The present invention relates to inter alia the use of known compounds for the treatment of seed.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080280952 - Pyridine derivatives as connabinoid receptor modulators: e

20080280954 - Method of improving wakefulness: The present invention relates to the use of certain imidazolylalkyl-pyridines as wakefulness compounds.... Agent: Hoffman Warnick LLC

20080280955 - Methods and compositions for screening and treatment of disorders of blood glucose regulation: In one aspect, the invention provides a method of screening and, optionally, treatment of an individual suffering from an insulin resistance disorder by screening an individual in need of treatment for an insulin resistance disorder for one or more genetic variations indicating a predisposition to a response to an insulin... Agent: Perlegen Sciences, Inc. Legal Department

20080280956 - Heteroarylsulfonyl stilbenes as 5-ht2a antagonists: Compounds of formula I: are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various 10 CNS disorders.... Agent: Merck And Co., Inc

20080280957 - Heterocyclic inhibitors of mek and methods of use thereof: Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.... Agent: Hogan & Hartson LLP

20080280958 - Topically applicable pharmaceutical preparation: A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.... Agent: Nath & Associates PLLC

20080280959 - Cyclic n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof: wherein the various R1-R9 substituents are defined herein. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080280961 - New amino-alkyl-amide derivatives as ccr3 receptor ligands: e

20080280960 - Waterbased bit/tmad formulations: Aqueous formulations having a pH of >10 of 1,2-benzoisothiazolin-3-one (BIT) and/or its alkali metal salts and tetramethylolacetylenediurea (TMAD) are outstandingly suitable for protecting industrial materials and products from infection and destruction by microorganisms.... Agent: Lanxess Corporation

20080280962 - Novel thiazolidin-4-one derivatives: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20080280963 - New amino-alkyl-amide derivatives as ccr3 receptor ligands: e

20080280964 - Novel antibiotics comprising bis(1-aryl-5-tetrazolyl)methane derivatives: The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds, the bis(1-aryl-5-tetrazolyl)methanes, which are especially useful for combating infections with gram-positive bacteria and especially MRSA.... Agent: Lucas & Mercanti, LLP

20080280965 - Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of g-protein coupled receptors (gpcps): The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in... Agent: Goodwin Procter L.l.p Attn: Patent Administrator

20080280966 - Hydroisoindoline tachykinin receptor antagonists: The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and... Agent: Merck And Co., Inc

20080280967 - Substituted acylhydroxamic acids and method of reducing tnfalpha levels: Imido and amido substituted acylhydroxamic acids which reduce the levels of TNFα and inhibit phosphodiesterase in a mammal. A typical embodiment is (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino)propanoate.... Agent: Jones Day

20080280968 - Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases: Disclosed are methods of treating infectious diseases comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent.... Agent: Knobbe Martens Olson & Bear LLP

20080280970 - Deuterium-enriched atorvastatin: The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080280971 - Deuterium-enriched atorvastatin: The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20080280969 - Novel compounds: The invention provides a compound of formula (I), pharmaceutical compositions thereof, and methods of treatment using the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080280972 - Iminosugar treatment of tumors: where R and R′ are each alkyl groups, R″ is hydrogen or an alkyl group and X3, X4 and X5 are each independently selected from the group consisting of hydrogen, benzyl, t-butyldimethylsiloxy radical and triphenylmethyl. Accordingly, compounds of formula (I) can be used for treatment of tumors including melanoma. Also... Agent: Foley And Lardner LLP Suite 500

20080280973 - Laulimalide analogues as therapeutic agents: Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described.... Agent: Robert E. Richards King & Spalding

20080280974 - Spiro compounds for treatment of inflammatory disorders: u

20080280975 - Methods of preventing the serotonin syndrome and compositions for use thereof: The present invention is directed at methods for preventing or minimizing the intensity of the serotonin syndrome in humans and lower animals which comprises administering proserotonergic agents and serotonin surge protectors. The present invention is also directed to pharmaceutical compositions comprising proserotonergic agents and serotonin surge protectors useful for carrying... Agent: Najib Badul

20080280976 - Composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity: The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR... Agent: Kirk Hahn

20080280977 - Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid: Provided are processes for the preparation of mycophenolate mofetil and other esters of mycophenolic acid.... Agent: Kenyon & Kenyon LLP

20080280978 - Insect repellent compositions: An insect repellent composition containing 3,8-p-menthane-diol and benzylbenzoate as active compounds is described. Typically, the active compounds are each present in the composition in an amount which is less than an amount of the compound required to be effective as an insect repellent by itself. The composition may additionally include... Agent: Ronald R. Santucci C/o Frommer Lawrence & Haug LLP

20080280979 - Methods and compositions of derivatives of probucol for the treatment of diabetes: This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a monoester of probucol, particularly the monosuccinic acid ester, or a pharmaceutically acceptable salt or derivative thereof.... Agent: King & Spalding LLP

20080280980 - Treatment and prevention of bone loss using resolvins: The present invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolvin. In particular, the inventive methods may be useful for treating or preventing... Agent: Choate, Hall & Stewart LLP

20080280981 - Tranexamic acid formulations: Disclosed are oral tranexamic acid formulations and methods of treatment therewith.... Agent: Davidson, Davidson & Kappel, LLC

20080280982 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using... Agent: Eli Lilly & Company

20080280983 - Methods of treating rett syndrome: The present embodiments relate to methods for the treatment of Rett Syndrome. More specifically, the present embodiments relate to pivagabine for use in the treatment of Rett Syndrome. Some embodiments relate to treatment of a patient with Rett Syndrome. Other embodiments relate to treatment of the indications of Rett Syndrome.... Agent: Knobbe Martens Olson & Bear LLP

20080280984 - Transdermal delivery of beneficial substances effected by a hostile biophysical environment: The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may... Agent: Wolf Greenfield & Sacks, P.C.

20080280985 - Methods and compositions using certain phenolic derivatives for the treatment of diabetes: This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a compound including an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer includes two groups... Agent: King & Spalding LLP

20080280986 - Treprostinil treatment for interstitial lung disease and asthma: The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates... Agent: Foley And Lardner LLP Suite 500

20080280987 - Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases: The invention provides methods of inhibiting angiogenesis in an individual by administering a composition (such as protein containing composition) comprising colchicine or thiocolchicine dimer. The composition is in an amount that is effective in inhibiting angiogenesis but is in some embodiments insufficient to induce significant cytotoxicity in the individual. The... Agent: Morrison & Foerster LLP

20080280988 - Use of (n'-methyl) benzoylurea compound: wherein R1 represents a hydrogen atom, a C1-C6 alkyl group optionally substituted with a halogen atom, or the like, R2 represents a halogen atom, or the like, and R3 represents a halogen atom, a C1-C4 alkyl group optionally substituted with a halogen atom, a C1-C4 alkoxy group optionally substituted with... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080280989 - Hydroxybenzamide derivatives, the method for preparing thereof and the cosmetic composition containing the same: Disclosed is a hydroxybenzamide derivative represented by the following Formula. A method for preparing the same and a cosmetic composition comprising the same are also disclosed. More particularly, the hydroxybenzamide derivative is obtained by reacting a hydroxybenzoic acid having a protecting group introduced thereto with a hydroxyphenyl amine to form... Agent: Nixon & Vanderhye, PC

20080280990 - Carboxamido opioid compounds: This invention is directed to carboxamido opioid compounds pharmaceutically useful as agents for treating or modulating a central nervous system disorder and methods for treating or modulating a central nervous system disorder.... Agent: Philip S. Johnson Johnson & Johnson

20080280991 - Substituted naphthalenes: Disclosed herein are substituted naphthalene-based melatonin (MT) receptor modulators and/or 5-HT receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080280992 - Pesticide bi-phenyl-amidine derivatives: The present invention relates to bi-phenyl-amidine derivatives of formula (I) in which the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of phytopathogenic fungi or damaging... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080280993 - Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20080280994 - Ascophyllum compositions and methods: The invention provides extracts of brown seaweed of the genus Ascophyllum that have valuable pharmacological properties. In particular, compositions of the invention are useful for e.g.: inhibiting alpha-glucosidase activity; preventing or treating conditions mediated by alpha-glucosidase activity; reducing blood glucose levels; preventing or treating diabetes; modulating glucose uptake in adipocytes;... Agent: Smart & Biggar P.o. Box 2999, Station D

20080280995 - Extracts of latex of calotropis procera and to a method of preparation thereof: The invention relates to aqueous suspension of dried latex (DL) of Calotropis procera and to a method of preparation for the prevention/treatment of cancer. The DL suspension when administered orally in the X-myc mice—a transgenic mouse model of hepatocellular carcinoma (HCC), was effective in protecting the animals from the atypical... Agent: The Webb Law Firm, P.C.

20080280996 - Use of carophyllenes in the manufacture of medicaments and treatment of bodily conditions of inflammation and inflammatory pain: The invention concerns the use of caryophyllenes related to medicaments and to the treatment of bodily conditions of inflammation and inflammatory pain.... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20080280997 - Novel pharmaceutical or cosmetic carriers containing cyclic acetals: The use of a cyclic acetal obtained by reacting an aliphatic aldehyde having 2 to 4 carbon atoms with a polyol having 3 to 6 carbon atoms and at least three hydroxy functions, including two on vicinal carbons or carbons having one carbon atom therebetween, as a pharmaceutical or cosmetic... Agent: Heslin Rothenberg Farley & Mesiti PC

20080280998 - Bifunctional derivatives of polyethylene glycol, their preparation and use: The patent describes homo- or hetero-bifunctional derivatives of polyethylene glycol (PEG) obtained by selectively modifying the hydroxyl end groups of commercial PEGs of different molecular weights with reactive bifunctional molecules. The synthesis process comprises steps involving sequential derivatization of PEG terminal hydroxyl groups with a bifunctional compound, purification of the... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080280999 - Process for making pharmaceutical compositions with a transient plasticizer: A process for making a solid oral dosage form that has a therapeutic compound (e.g., a poorly soluble and/or poorly compactible therapeutic compound) and a polymer. The process is accomplished by the use of an extruder. A transient plasticizer, e.g., a liquefied gas such as supercritical carbon dioxide, is added... Agent: Novartis Corporate Intellectual Property

20080281000 - Hydrophobic polysaccharide derivatives: Novel cross-linked gels comprised of alkoxyetheramides grafted to polysaccharides that have superior viscosity properties have been made. By controlling the chain length of the alkoxyetheramides and the hydrophobic nature of the gel, these materials are ideal for many uses such as in hydraulic fracturing of oil-bearing geological formations, in the... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20080274945 - Infant nutrition with protease inhibitor: Provided is an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of childhood obesity and secondary disorders resulting from childhood obesity.... Agent: Foley And Lardner LLP Suite 500

20080274946 - Method and composition for restoration of age related tissue loss in the face or selected areas of the body: A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face,... Agent: Melvin K. Silverman And Assocs PC

20080274947 - Hydroxy-substituted diphenylazetidinones for the treatment of hyperlipidemia: t

20080274950 - Cell adhesion by modified cadherin molecules: The potential role of so called ‘cell adhesion recognition motifs’ (CARs) in cadherin adhesion has been emphasized. Due to the importance of cadherin binding in biological process, there remains a need to develop effective ways of manipulating cadherin adhesion. According to the present invention, there is provided a pair of... Agent: Proskauer Rose LLP

20080274948 - Conjugates of hydroxyalkyl starch and g-csf: The present invention relates to conjugates of hydroxyalkyl starch and a granulocyte colony stimulating factor protein (G-CSF) wherein these conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. The present invention also relates to the methods of producing... Agent: Fish & Richardson P.C.

20080274949 - Formulation of albumin-free erythropoietin: Disclosed is a stable pharmaceutical solution preparation of erythropoietin (EPO), which includes a stabilizing agent not containing a blood-derived protein, thereby maintaining EPO activity for a prolonged period of time without the risk of viral contamination. The stable solution preparation further includes a non-ionic surfactant and a tonicity agent, thereby... Agent: Casimir Jones, S.c.

20080274951 - Pharmaceutical compositions including low dosages of desmopressin: The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin... Agent: Goodwin Procter LLP Patent Administrator

20080274973 - novel haemopoietin receptor and genetic sequences encoding same: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists,... Agent: Scully Scott Murphy & Presser, PC

20080274959 - Actinomadura chromoprotein, apoprotein and gene cluster: The present invention provides a chromoprotein produced by Actinomadura sp. 21G792, as well as amino acid and nucleic acid sequences of the apoprotein component of the chromoprotein and of components of the biosynthetic pathway for the chromophore. The present invention is useful for developing pharmaceutical and treating diseases such as... Agent: Wyeth Patent Law Group

20080274969 - Albumin-fused kunitz domain peptides: The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins... Agent: Fox Rothschild LLP

20080274952 - Amylin family peptides and methods for making and using them: The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080274966 - Biglycan and related therapeutics and methods of use: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those... Agent: Ropes & Gray LLP

20080274965 - Encapsulated amyloid-beta peptides: The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.... Agent: Choate, Hall & Stewart LLP

20080274960 - Fibrosis inhibitor for implanted organ: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080274956 - Fusion protein comprising a bh3-domain of a bh3-only protein: This invention relates to a fusion protein comprising at least one first portion (I) comprising a trafficking sequence and at least one second portion (II) comprising a full-length or partial BH3-domain sequence of a BH3-only protein, said fusion protein comprising D-enantiomeric amino acids in retro-inverso order in its portion (I).... Agent: Sughrue Mion, PLLC

20080274954 - Gene encoding a guanine nucleotide exchange factor and its gene product: A gene encoding a novel protein having a guanine nucleotide exchange factor (GEF) activity for a Rho family protein being one group of small GTP binding proteins, namely, a polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO:... Agent: Kilyk & Bowersox, P.l.l.c.

20080274958 - Glycosylation of peptides via o-linked glycosylation sequences: The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries... Agent: Morgan, Lewis & Bockius LLP (sf)

20080274964 - Human spasmolytic polypeptide in glycosylated form: e

20080274968 - In vitro methods for detecting renal cancer: The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search,... Agent: Intellectual Property / Technology Law

20080274953 - Method of preparing a protein aggregate and a pharmaceutical preparation: The invention relates to a method of preparing a protein aggregate, wherein an aqueous protein solution is acidified with a pH that lies above the isoelectric point of the protein. In accordance with the invention, a first protein, which through acidification is able to form a protein aggregate, is acidified... Agent: Akerman Senterfitt

20080274963 - Modulation of granulosa cell apoptosis: The present invention relates to a method of modulating apoptosis of a granulosa cell. The method includes one or more of the following steps: (i) modulating the concentration and/or activity of BMP-15 and/or BMP-6 that the granulosa cell is exposed to; (ii) modulating activity of a BMP-15 dependent signalling pathway... Agent: Birch Stewart Kolasch & Birch

20080274955 - Novel use of a polypeptide comprising fas-1 domain: The present invention relates to the novel use of a polypeptide comprising a fas-1 domain. More particularly, the invention relates to a method for the inhibition of the adhesion, migration and/or proliferation of endothelial cells, and/or for the inhibition of angiogenesis, using the polypeptide comprising the fas-1 domain, or functional... Agent: Buchanan, Ingersoll & Rooney PC

20080274974 - Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process: A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the... Agent: Darby & Darby P.C.

20080274957 - Rgd-enriched gelatine-like proteins with enhanced cell binding: The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at... Agent: Ip Patent Docketing K&l Gates LLP

20080274972 - T-cell epitope peptides: The T-cell epitope site on a Japanese cypress (hinoki) pollen allergen molecule has been identified by stimulating a T-cell line established from a patient suffering from Japanese cypress pollen allergy with an overlap peptide covering the primary structure of the Japanese cypress pollen allergen. The peptide is useful in peptide-based... Agent: Fish & Richardson P.C.

20080274971 - Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation: The present invention relates to the field of muscle research, in particular to the discovery of a compound effective for increasing muscle mass, muscle cell differentiation, and oxidation of free fatty acids in muscle, useful in methods of treating muscle-related diseases and disorders as well as for augmenting muscle mass... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080274961 - Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis: The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to sarcoidosis. The peptides which can be used according to the invention for the treatment of said disease comprise at least one specific highly conservative amino acid residue... Agent: Winstead PC

20080274967 - Variants of pigment epithelium derived factor and uses thereof: The present invention relates to anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising a plurality of altered phosphorylation sites, polynucleotides encoding same and uses thereof. In particular, the PEDF variants of the present invention provide superior anti-angiogenic activity and high neurotrophic activity and are useful in treating diseases associated... Agent: Fennemore Craig

20080274970 - Vascular adhesion molecules and modulation of their function: The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. 3, upper... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080274962 - Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis: The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC)5 polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating... Agent: Fennemore Craig

20080274975 - Methods and compositions for inhibiting abad/abeta protein interaction: This invention provides methods, compositions and articles of manufacture for inhibiting binding between Aβ protein and ABAD in cells. Uses of this invention include, for example, treating Alzheimer's disease; reducing free radical generation, DNA fragmentation, and cytochrome C release in cells; and preserving cell viability by preventing LDH release from... Agent: Cooper & Dunham, LLP

20080274977 - Treating stroke and other diseases without inhibiting n-type calcium channels: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial... Agent: Townsend And Townsend And Crew, LLP

20080274976 - Uses of novel potassium channel blockers: The present invention is directed to kappaM (κM) conopeptide RIIIK and its use for blocking the flow of potassium ions through voltage-gated potassium channels. The κM conopeptides include unglycosylated and O-glycosylated peptides.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080274978 - Peptides that antagonize fpr class receptor mediated signaling: The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.... Agent: Jhk Law

20080274979 - Treatment of leaky or damaged tight junctions and enhancing extracellular matrix: Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080274980 - Macromonomers and hydrogel systems using native chemical ligation, and their methods of preparation: The present invention provides novel biocompatible macromonomers, hydrogels, methods of synthesis and methods of use thereof. The biocompatible hydrogels of the present invention are prepared using native chemical ligation (NCL), in which a thioester readily reacts with a N-terminal thiol (cysteine) through transesterification and rearrangement to form an amide bond... Agent: Quarles & Brady LLP

20080274983 - Amelioration of the development of cataracts and other ophthalmic diseases: e

20080274982 - Peptide substance restoring respiratory organs function: The invention refers to the medicinal remedies for respiratory system diseases treatment and may be applied as a substance, capable of restoring respiratory organs functions and used for treatment of different forms of lung pathology. There is proposed a biologically active new tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, capable... Agent: Leydig Voit & Mayer, Ltd

20080274984 - Method, composition and kit for antigenic binding of norwalk-like viruses: A method for detecting a Norwalk-Like Virus (NLV) in a biological sample, comprising the steps of: obtaining a biological sample suspected of containing a NLV; contacting the biological sample with at least one human histo-blood group antigen to allow formation of a complex of the NLV with the antigen; and... Agent: Hasse & Nesbitt LLC

20080274985 - Pharmaceutical composition useful for the treatment of peptic ulcer diseases: The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant Woodfordia fruticosa optionally along with one or more pharmaceutically acceptable carriers, additives, lubricants and diluents. Further it also provides a method of treating peptic ulcer... Agent: Edwards Angell Palmer & Dodge LLP

20080274986 - Pharmaceutical vehicle: A pharmaceutical solution is capable of being ejected from a thermal fluid ejection device onto a substrate. The solution includes a vehicle with predetermined properties, and an active pharmaceutical ingredient with a solubility of at least about 30 mg/ml in the vehicle. The vehicle substantially evaporates from the substrate.... Agent: Hewlett Packard Company

20080274987 - Novel alpha glucosidase activator, pulicarside 1: A new ent-kaurane type diterpene glucoside, pulicarside (1) was isolated from Pulicaria undulate with a strong α-glucosidase promoter activity; a large number of clinical applications are provided.... Agent: Sarfaraz K. Niazi

20080274988 - Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection: The present invention discloses disease-associated molecules and assays, which are useful for diagnosing and assessing those animals with herpes virus infection, and determining those animals at risk of developing an herpes virus infection or its sequelae. The invention has practical use in the early diagnosis of disease, in monitoring an... Agent: Proskauer Rose LLP

20080274994 - Cardiac myosin light chain kinase and methods of use: The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or... Agent: Klarquist Sparkman, LLP

20080274990 - Cog47 protein and s100beta gene polymorphism: The invention concerns a Cog47 protein and its polynucleotide, in particular associated with a predisposition to cognitive decline, to a conversion to dementia or to an already existing dementia, and the human S100β gene exhibiting a polymorphism associated with a predisposition to cognitive decline, to a conversion to dementia or... Agent: Foley And Lardner LLP Suite 500

20080274993 - Methods and compositions for modulating vascular integrity: The invention provides methods and compositions useful for modulating vascular integrity.... Agent: Genentech, Inc.

20080274991 - Nucleic acids against viruses, in particular hiv: The invention provides a nucleic acid molecule comprising a sequence that is complementary to a mutant of a genomic nucleic acid sequence of an organism capable of mutating its genome. The genomic nucleic acid sequence preferably comprises a conserved, essential region. Furthermore, the genomic nucleic acid sequence preferably comprises a... Agent: Trask Britt

20080274992 - Recombinant modified ankara viral hiv-1 vaccines: The field of the present invention relates to novel recombinant MVA vectors encoding one or more HIV-1 immunogens as an HIV-1 vaccine candidate and methods of using same.... Agent: Frommer Lawrence & Haug

20080274989 - Rna interference suppression of neurodegenerative diseases and methods of use thereof: The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules.... Agent: Viksnins Harris & Padys Pllp

20080274996 - Rnai probes targeting cancer-related proteins: RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2,... Agent: Marina Larson & Associates, LLC

20080274995 - Suppression of nuclear factor-kappab dependent processes using oligonucleotides: Antisense oligonucleotides which hybridize with nuclear factor-κB (NF-κB) mRNA and methods of using these oligonucleotides.... Agent: Dla Piper US LLP

20080274997 - Stable granulates containing s-adenosylmethionine and process for preparation thereof: t

20080274998 - Disaccharide molecules and derivatives thereof and methods of using same: The present invention is of a method and compounds for mediating a biological activity mediated by moesin, and in particular, for such a method and compounds for mediating a biological activity that is capable of being mediated through binding of a disaccharide to moesin.... Agent: Martin D. Moynihan Prtsi

20080275000 - Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same: Compositions for relief, treatment, or prevention of a condition of dry eye comprise alginate, a polyol, and a combinations of at least two organic acids or salts thereof, wherein the compositions have pH in the range from about 5 to about 7.5, at least one of the organic acids or... Agent: Bausch & Lomb Incorporated

20080274999 - Hyaluronic acid fraction with moisturizing and anti-wrinkle properties: A moisturizing, cosmetic, or anti-wrinkle product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid or salt thereof has an average molecular weight in the range of 0.7-0.9 MDa, compositions comprising said product, and uses of said product.... Agent: Novozymes North America, Inc.

20080275001 - Solid oral dosage form containing an enhancer: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty... Agent: Myers Bigel Sibley & Sajovec

20080275002 - Method for treatment of hepatic cancer: A method for therapeutic treatment of hepatic cancer, which comprises the step of administering 10 to 30 mg per day of 4-[3,5-bis(trimethylsilyl)benzamido]-benzoic acid or a physiologically acceptable salt thereof to a patient with hepatic cancer.... Agent: Greenblum & Bernstein, P.L.C

20080275003 - Bis-cationic compounds and use thereof: The present invention relates to bis-cationic compounds comprising quaternary ammonium groups and/or quaternary phosphonium groups. The invention also relates to the use of bis-cationic compounds as Phospholipase B inhibitors and the use of bis cationic compounds for the treatment or prevention of microbial infection.... Agent: Quarles & Brady LLP

20080275004 - N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed... Agent: Merck And Co., Inc

20080274981 - Compositions and methods for regulating apoptosis: Peptides and peptidomimetics capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The peptides and mimetics are based on the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed... Agent: Pepper Hamilton LLP

20080275005 - Mitochondrially targeted antioxidants: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR.Z- where X is a linking group, Z is an... Agent: Seed Intellectual Property Law Group PLLC

20080275008 - Aminophosphonic acid derivative, salt thereof, and modulator of sip receptor: e

20080275007 - Charged phospholipid compositions and methods for their use: The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of... Agent: Smart & Biggar P.o. Box 2999, Station D

20080275006 - Process for the preparation and isolation of phosphatides: e

20080275010 - Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium);... Agent: Wilmerhale/dc

20080275009 - Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof: Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080275011 - Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events: This invention relates to a method of treating and preventing vascular events and circulatory disorders in a patient in need thereof, especially in a patient at risk for said indications, using dipyridamole in combination with acetylsalicylic acid (ASA) and an angiotensin II antagonist, corresponding pharmaceutical compositions, and the use of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080275012 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Fox Rothschild LLP

20080275013 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Fox Rothschild LLP

20080275014 - Clobetasol propionate shampoos for the treatment of seborrheic dermatitis of the scalp: Seborrheic dermatitis is effectively/safely treated by topically applying a corticosteroid shampoo, notably a clobetasol propionate shampoo, onto the scalp of a human subject afflicted therewith.... Agent: Buchanan, Ingersoll & Rooney PC

20080275015 - Formulation and method for treating interstitial cystitis and related bladder conditions: The invention of this application relates to a formulation and method of using the formulation for the treatment of interstitial cystitis and other similar conditions of the bladder. The formulation of this invention is a highly specialized, compounded pharmaceutical that contains a combination of numerous therapeutically different medications in a... Agent: Buckingham, Doolittle & Burroughs, LLP

20080275017 - Aromatic sulfenates for type i phototherapy: Novel sulfenate derivatives and their bioconjugates for phototherapy of tumors and other lesions. The sulfenates of the present invention are designed to absorb low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of free radicals, the reactive intermediate produced upon... Agent: Thompson Hine L.L.P. Intellectual Property Group

20080275016 - Fulvene and fulvalene analogs and their use in treating cancers: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular... Agent: Intellectual Property / Technology Law

20080275018 - Antibacterial amide-macrocycles v: The invention relates to antibacterial amide-macrocycles of formula (I), in which R26 represents hydrogen, halogen, amino or methyl, R7 represents a group of formula (II), (III), (IV) or (V), whereby R1 represents hydrogen or hydroxy and * is the linkage site to the carbon atom, R2 represents hydrogen or methyl... Agent: Morrison & Foerster LLP

20080275019 - Metal complex protein kinase inhibitors: This inventive subject matter relates to novel metal complex protein kinases inhibitors, methods for making such compounds, and methods for using such compounds for treating diseases and disorders mediated by kinase activity.... Agent: Woodcock Washburn LLP

20080275020 - Pharmaceutical formulation: The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.... Agent: Foley And Lardner LLP Suite 500

20080275021 - Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists: e

20080275022 - Substituted quinazolones as anti-cancer agents: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20080275023 - N-hydroxyamides omege-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations: New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC).... Agent: Jay S. Cinamon Abelman Frayne & Schwab

20080275024 - Cyclic malonamides as inhibitors of ass protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20080275025 - Substituted lactams and their use as anti-cancer agents: This invention relates to certain substituted lactam compounds, particularly caprolactam compounds, which are useful for the treatment of cancer.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080275026 - Benzamide derivatives as oxytocin agonists and vasopressin antagonists: Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or V1a receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.... Agent: Foley And Lardner LLP Suite 500

20080275027 - Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists: v

20080275028 - Modulators or alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof: The present invention relates to compounds with α7 nAChR agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological, psychiatric, cognitive, immunological and inflammatory disorders.... Agent: Choate, Hall & Stewart LLP

20080275029 - Compounds for treating protein-kinase mediated disorders: wherein the ring Q is a benzene ring; J2-J1 is N═CR7 or R1aN—CO; G is OH or NR5R6; E is CONR7, NR7CO, C(R8)═C(R8) or (X)m(CR8R8a)n where X is O, S or NR7; provided that when J2-J1 is R1aN—CO, E is other than NR7CO; m and n are each 0 or... Agent: Heslin Rothenberg Farley & Mesiti PC

20080275030 - Methods and compositions for the delivery of a therapeutic agent: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods... Agent: Goodwin Procter LLP Patent Administrator

20080275031 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20080275032 - Pyridazinone compounds: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20080275033 - Biologically active methylene blue derivatives: e

20080275034 - Use of a phenothiazine derivative for preventing and/or treating hearing loss: The invention concerns the use of a phenothiazine derivative of formula (I), wherein: R represents the hydrogen atom, an alkyl radical, arylalkyl, or —C(O)R′, for preparing a medicine for preventing and/or treating hearing loss.... Agent: Hunton & Williams LLP Intellectual Property Department

20080275035 - Nitroimidazole compounds: The present invention relates to certain nitroimidazole compounds, which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Mycobacterium tuberculosis, Trypanosoma cruzi or Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well... Agent: Novartis Corporate Intellectual Property

20080275036 - Prevention and treatment of cardiac conditions: The present invention provides a method of treating conditions associated with iron and calcium overload comprising administering an effective amount of dexrazoxane or a non-dexrazoxane compound of formula (IA), (IB), or (IC) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.... Agent: Woodcock Washburn LLP

20080275037 - 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof: e

20080275038 - Imidazopyridine derivatives as a2b adenosine receptor antagonists:

20080275039 - Geldanamycin derivatives and the method for biosynthesis thereof: The present invention relates to geldanamycin derivatives, benzoquinone ansamycin biosynthesized by gene manipulation of Streptomyces hygroscopicus subsp. duamyceticus and the method producing them, more particularly to a geldanamycin O-carbamoyl transferase gene(gel8)-inactive mutant, the method producing it and geldanamycin derivatives, 4,5-dihydro-7-O-descarbamoyl-7-hydroxy geldanamycin and 4,5-dihydro-7-O-descarbamoyl-7-hydroxy-17-O-demethyl geldanamycin. Since geldanamycin derivatives of the present... Agent: Lucas & Mercanti, LLP

20080275041 - 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3): e

20080275042 - 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives for the treatment of infertility: The present invention relates to 4-phenyl-5-oxo-1,4)5,6,7,8-hexahydroquinoline derivatives according to Formula I, Formula I or a pharmaceutically acceptable salt thereof, wherein R1 is (1-6C)alkyl, (2-6C)alkenyl or (2-6C)aDcynyl; R2, R3 are independently halogen, (1-4C)allyl, (2-4C)alkenyl, (2-4C)-alkynyl, (1-4C)aBcoxy, (3-4C)alkenyloxy or (3-4C)alkynyloxy; R4 is phenyl or (2-5C)-heteroaryl, both substituted with R7 and optionally substituted... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080275040 - 8-(1-piperazinyl)-quinoline derivatives and their use in the treatment of cns disorders: This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080275043 - Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to... Agent: Eli Lilly & Company

20080275044 - Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions: e

20080275045 - Potassium channel modulating agents and their medical use: Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular respiratory diseases, epilepsy, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel... Agent: Birch Stewart Kolasch & Birch

20080275046 - Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses: The present invention relates to compounds comprising an oxazole or thiazole moiety of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, Formula (I), wherein, A1 is CH, C(alkyl), C-halogen or N; R1 is hydrogen, halogen, C1-6 alkyl or alkoxy; R2 is,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080275047 - Tetrahydro-naphthalene derivatives: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tethrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment... Agent: Baker Botts L.L.P.

20080275048 - Substituted diazabicycloalkane derivates: wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with... Agent: Paul D. Yasger Abbott Laboratories

20080275049 - Methods and compositions for upregulation of gata activity: A novel method of identifying compounds capable of upregulating GATA activity is disclosed. The method includes providing a sample of cells that express GATA, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of GATA activity within the cell... Agent: Dority & Manning, P.A.

20080275050 - Pyridazine compound and use thereof: n

20080275052 - Heterobicyclic compounds useful as kinase inhibitors:

20080275051 - Preparation of high purity substituted quinoxalines: The present invention comprises an improved process for the preparation of substituted quinoxaline I by cyclization of the corresponding dianiline.... Agent: Pfizer Inc Steve T. Zelson

20080275053 - Heterocyclyl compounds: e

20080275054 - 3-(substituted amino)-pyrazolo[3, 4-d]pyrimidines as ephb and vegfr2 kinase inhibitors:

20080275055 - Imatinib production process: Provided is a process for producing imatinib and salts thereof, e.g., imatinib mesylate. The process includes reacting4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid with N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine in the presence of a carboxylic acid coupling reagent, to produce imatinib, and optionally converting the imatinib into a salt.... Agent: Leydig Voit & Mayer, Ltd

20080275056 - Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors: The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.... Agent: Eli Lilly & Company

20080275057 - Compounds with anti-cancer activity: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080275058 - N-substituted-1h-quinoline-2,4-diones, preparation method thereof, and pharmaceutical composition containing the same: The present invention relates to compounds of N-substituted -1H-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of N-substituted-1H-quinoline-2,4-diones according to the present invention have excellent binding affinity for the 5HT6... Agent: Lucas & Mercanti, LLP

20080275059 - Novel physiologically active substances: (wherein, R3, R6, R7 and R21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition... Agent: Birch Stewart Kolasch & Birch

20080275060 - N-hydroxyamide derivatives and use thereof: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080275061 - Method for controlling particular insect pests by applying anthranilamide compounds: e

20080275062 - Chemical compounds:

20080275063 - Inhibitors of protein kinases: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.... Agent: Olson & Cepuritis, Ltd.

20080275064 - Substituted pyrimidines as adenosine receptor antagonists: Compounds of formula (I), including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof as antagonists of adenosine receptors, in particular antagonists of the A2A adenosine... Agent: Neurocrine Biosciences, Inc.

20080275065 - Novel insecticides: m

20080275066 - Condensed thiophene derivatives and their use as cyclic glp-1 agonists: The invention provides compounds of formula (I) for use as GLP-1 receptor agonists.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080275067 - Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta: Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.... Agent: Morrison & Foerster LLP

20080275068 - Method of using vasoconstrictive agents during energy-based tissue therapy: A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the... Agent: Tyco Healthcare Group Lp

20080275069 - Quinazoline derivative: X1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic... Agent: Merck And Co., Inc

20080275070 - Aryl ether compounds and their preparation and use thereof: The groups are as defined as specification. The aryl ether compounds of present invention have wide spectrum fungicidal activity, and may be used to control diseases in all sorts of plants caused by oomycete, basidiomycete, ascomycete pathogens and deuteromycete. The some of the compounds have very good insecticidal and acaricidal... Agent: Smith, Gambrell & Russell

20080275071 - Radiotherapy enhancer: The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080275072 - Weekly administration of dipeptidyl peptidase inhibitors: Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.... Agent: Mitchell R. Brustein Takeda San Diego, Inc.

20080275073 - Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts: a

20080275074 - Anti-itching agent:

20080275075 - Medicine comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative: wherein Het is oxadiazolyl; R1 is hydrogen atom, lower alkyl, lower cycloalkyl, lower alkenyl, lower alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, etc., and R2 is hydrogen atom, lower alkyl, a lower cycloalkyl, substituted or unsubstituted aryl, etc., which is useful for treating neuropsychiatric disease-accompanying dysmnesia and other... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080275076 - Pharmaceutical compositions comprising sirolimus and/or an analogue thereof: The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising sirolimus (rapamycin) and/or derivatives and/or analogues thereof. Compositions of the invention exhibit an acceptable bioavailability of sirolimus and/or a derivative and/or an analogue thereof. The pharmaceutical compositions of the invention are designed to release... Agent: Cheryl H Agris Phd

20080275077 - Pharmaceutical formulations comprising an immune response modifier: Pharmaceutical formulations comprising an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-quinolineamines, oxazolo-quinolinamines, thiazolo-pyridinamines, oxazolo-pyridinamines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the... Agent: 3m Innovative Properties Company

20080275078 - Pyrazolo[3,4-b] pyridine compounds and their use as pde4 inhibitors: a

20080275079 - M3 muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080275080 - Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in... Agent: Alston & Bird LLP

20080275081 - Novel thrombomodulin expression promoters: It is intended to provide a novel pharmaceutical effect of HMG-COA reductase inhibitors, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-di hydroxy-6-heptenoic acid or its salt. Namely, TM expression promoters, more specifically speaking, antithrombotic drugs, preventive/remedies for sepsis, antiplatelet drugs and anticoagulants comprising as the active ingredient an HMG-COA reductase inhibitor, in particular,... Agent: Edwards Angell Palmer & Dodge LLP

20080275082 - Pharmaceutical composition: A novel pharmaceutical composition comprising the NK3 receptor antagonist talnetant, povidone, erythritol and a surfactant, and a process for its preparation are disclosed. The use of erythritol as soluble filler in the preparation of a stable pharmaceutical composition is disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080275083 - 2,3,4,9-tetrahydro-1h-carbazoles: n

20080275084 - Piperidines for the treatment of chemokine mediated diseases: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.... Agent: Fish & Richardson P.C.

20080275085 - Piperidine derivative and use thereof: e

20080275086 - Dpp-iv inhibitors:

20080275087 - Biphenylcarboxamides useful as lipid lowering agents:

20080275088 - Use of collismycin and derivatives thereof as oxidative stress inhibitors: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.... Agent: Intellectual Property / Technology Law

20080275090 - Amino-benzazoles as p2y1 receptor inhibitors with pyridine ring and heterocyclic components: The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080275091 - Compositions and methods for treating nocturnal acid breakthrough and other related disorders: The present invention relates to, inter alia, pharmaceutical compositions comprising an acid labile proton pump inhibitor and a buffering agent; to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders.... Agent: Mayer Brown LLP

20080275089 - Compositions and methods to treat gastrointestinal disorders: The invention provides safe and effective methods for treating and preventing dysphagia, lower esophageal mucosal rings, esophageal strictures, achalasia, gastric mucosal injuries, and bacterial infections. The methods comprise administering at least one proton pump inhibitor, optionally in combination with antibacterial compounds. In one embodiment, the proton pump inhibitor is rabeprazole,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080275092 - Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors: and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or —C(═O)NR6, wherein R6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous... Agent: Louis J. Wille Bristol-myers Squibb Company

20080275093 - Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use: The invention describes novel diuretic compounds comprising at least one heterocyclic nitric oxide donor group, or pharmaceutically acceptable salts thereof, and novel composition comprising at least one diuretic compound comprising at least one heterocyclic nitric oxide donor group, and optionally, at least one nitric oxide enhancing compound and/or at least... Agent: Wilmerhale/nitromed

20080275094 - 5-(1,3-diaryl-1h-pyrazol-4-1 methylene)-thiazolidine-2,4-dione derivatives useful as anticancer agent: The present invention relates to a 5-(1,3-diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine-2,4-dione derivative or its pharmaceutically acceptable salts thereof, a method for preparing the same and an anticancer agent composition comprising the same as an active ingredient.... Agent: Ronald R. Santucci Frommer Lawrence & Haug

20080275095 - Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases: This invention relates to methods for treating renal diseases by using combination of prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor and pharmaceutical compositions for treating renal diseases comprising prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080275096 - Process for the preparation of valsartan: Provided is a process for preparing valsartan and precursors thereof.... Agent: Kenyon & Kenyon LLP

20080275097 - Non-nucleoside reverse transcriptase inhibitors: are HIV reverse transcriptase inhibitors, wherein V, W, X, Y, Z, R1, R2, R4, R5, R6, ring A, ring B, j and k are defined herein. The compounds of Formula I, and the pharmaceutically acceptable salts and prodrugs thereof, are useful in the inhibition of HIV reverse transcriptase, the prophylaxis... Agent: Merck And Co., Inc

20080275098 - Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid: e

20080275100 - Propofol analogs, process for their preparation, and methods of use: The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient.... Agent: Leydig Voit & Mayer, Ltd

20080275099 - Solid forms of (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone oxime: Solid forms of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime, compositions comprising them, and methods of their use are disclosed.... Agent: Lexicon Pharmaceuticals, Inc.

20080275101 - Solid salt forms of a pyrrole substituted 2-indolinone: The present invention relates to solid salt forms of the 3-pyrrole substituted 2-indolinone compound 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide. It also relates to polymorphs of the phosphate salt of the amide. The invention further relates to the use of the salts and polymorphs in the treatment of protein kinase related disorders.... Agent: Pharmacia & Upjohn

20080275102 - 3-acylindole derivatives, preparation and therapeutic use thereof: e

20080275103 - Anti-tubulin acting arylpyrrol, arylfuran and arylthiophene derivatives, method for the preparation thereof and for the use thereof as an antimitotic: The invention relates to a compound represented by general formula (I) wherein Z represents N, O or S, and A represents a CH group, a nitrogen atom or an NL+ group wherein L represents a straight-chained or branched C1-C12 alkyl group. The invention also relates to a method for the... Agent: Alston & Bird LLP

20080275104 - Methods of treating juvenile type 1 diabetes mellitus: The present disclosure describes methods for treating Type 1 diabetes mellitus in juveniles. This treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of... Agent: Fulbright & Jaworski L.L.P.

20080275105 - Selective muscle relaxant and pharmaceutical compositions: This invention refers to substances able to cause selective muscle relaxation, pharmaceutical compositions containing such compounds and their use in the treatment of muscle tissue diseases, with such compounds complying with the general formula (I).... Agent: Smith, Gambrell & Russell

20080275106 - Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities: This invention comprises compositions containing dihydroartemisinin- and dihydroartemisitene-dimers with activity as anticancer or anticancer metastasis agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer or prevention of cancer metastasis,... Agent: Hunton & Williams/new York Intellectual Property Dept.

20080275107 - Topical formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice with multiple modes of action: Topical formulations for prophylaxis or elimination of susceptible and treatment resistant head lice wherein the formulation is an aqueous dispersion of an oil phase containing an effective amount of an active ingredient component combining at least one compound that binds to glutamate-gated chloride ion channels and at least one compound... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080275108 - Vacuolar-type (h+)-atpase-inhibiting compounds, compositions, and uses thereof: wherein R1 and R2 are H, saturated or unsaturated alkyl, aryl, R6CH2—, R6CO—, or R6SO2—, wherein R6 is H, saturated or unsaturated alkyl, or aryl; R3 is H, alkyl, aryl, an oxime, or an oxime methyl ether; the aromatic ring is unsubstituted or substituted; and Z is a contiguous linker... Agent: Leydig, Voit & Mayer, Ltd.

20080275109 - Neutralizing agent for vacuolating toxin: A drug, quasi drug, food or drink product containing a proanthocyanidine derived from hop, hop bract or apple has the effect of neutralizing or attenuating a vacuolacting toxin produced by Helicobacter pylori, thus preventing, preventing recurrence or treating digestive diseases in which Helicobacter pylori participates, as well as killing Helicobacter... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080275111 - Novel use of lignan compounds: The present invention relates to the novel use of lignan compounds represented by Formula I. More particularly, the present invention relates to a pharmaceutical composition for treating or preventing a brain disease, comprising a lignan compound represented by Formula I or a Myristica fragrans extract as an active ingredient, as... Agent: Jhk Law

20080275110 - Sesamin/episesamin compositions: Sesamin and episesamin are incorporated at specified weight ratios in oral compositions so that the oral absorption of episesamin and/or its transfer into blood circulation is increased. Sesamin and episesamin are also incorporated at specified weight ratios in oral compositions so that the physiological activities of sesamins are enhanced.... Agent: Drinker Biddle & Reath (dc)

20080275112 - Invention concerning aminoadamantane compounds: The present invention describes 1-aminoadamantane derivatives and 3-aminoadamantane-1-carboxylic derivatives in which the 5- or 7-position of the basic adamantane structure can be optionally substituted, methods for the production of the compounds based on the present invention, and methods for the coupling of the monomeric 3-aminoadamantane-1-carboxylic derivatives thus obtained to oligomers.... Agent: Clark & Brody

20080275113 - Antimicrobial compositions, products, and methods of use: The present invention comprises an antimicrobial composition. More particularly to an antimicrobial composition that comprises a. from about 0.01% to about 15% of at least one non-anionic surfactant, by weight of the composition; b. from about 0.01% to about 15% of at least one acid, by weight of the composition;... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080275114 - Inhibitors of ccr9 activity: Compounds of formula (I), in which R1 and R2 are independently a substituted phenyl group, where the substituents are as defined in the claims and with the proviso that at least one of the substituents is a cyano, carboxy or (C1-4)alkoxycarbonyl group, are inhibitors of CCR9 activity useful for therapeutic... Agent: Novartis Corporate Intellectual Property

20080275116 - Carboxilic acid derivatives: wherein R1 represents a C6-10 aryl group; or a substituted C6-10 aryl group, R2 represents a C6-10 aryl group; or a C6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, nitro group, a C1-6 alkyl group, a halogenated C1-6 alkyl group,... Agent: Greenblum & Bernstein, P.L.C

20080275115 - Insecticidal compositions suitable for use in preparation of insecticidal granular fertilizer and insecticidal formulations: Insecticidal compositions suitable for use in preparation of insecticidal granular fertilizer and insecticidal formulations comprising a pyrethroid and a glycol present in a concentration of from 40.0% by weight to 99.0% by weight based upon the total weight of all components in the composition is disclosed.... Agent: Patent Administrator Fmc Corporation

20080275117 - Compositions and methods comprising boswellia species: In certain aspects the invention features novel compositions and pharmaceutical preparations of the same. In certain embodiments, the compositions comprise α- and/or β-boswellic acid and/or their C-acetates in an amount greater than 65% by weight.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080275118 - Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss: This invention relates to compositions and processes for stimulating the growth of mammalian hair comprising the topical application of compositions comprising a hair growth stimulating and/or hair loss prevention agent, and a hair and/or skin lightening and/or neutralization agent, in association with a topical pharmaceutical carrier. Unlike other products, the... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080275119 - Treatment and prevention of liver disease associated with parenteral nutrition (pn): The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty... Agent: David S. Resnick

20080275120 - Leucine rich composition: The invention relates to the use of a composition comprising proteinaceous matter, said providing at least 24.0% of the energetic value of the composition (en %) and at least 12 wt. % based on proteinaceous matter leucine in the manufacture of a medicament for the treatment of insulin resistance and... Agent: Banner & Witcoff, Ltd.

20080275123 - N-halogenated amino acid formulations: The present invention relates to a method for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a phase transfer agent. This specification also describes a formulation having antimicrobial activity comprising a N-halogenated amino acid and... Agent: Alcon

20080275121 - N-halogenated amino acid formulations and methods for cleaning and disinfection: The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a... Agent: Alcon

20080275122 - N-halogenated amino acid formulations with anti-inflammatory compounds: The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory... Agent: Alcon

20080275124 - Powder of amino acids and method for producing the same: Dry powders of amino acids which exhibit great oral meltability and solubility, may be produced by spray drying a hydrous liquid of amino acids to produce a powder of amino acids, where the hydrous liquid of amino acids is prepared into the form of microfine liquid droplets in the presence... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080275125 - Combination composition: A combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol.... Agent: Matthias Scholl

20080275126 - Aliphatic acid-containing n-halogenated amino acid formulations: The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding... Agent: Alcon

20080275127 - Arylsulfonamido-substituted hydroxamic acid derivatives: e

20080275128 - Compositions and methods for the treatment of inflammatory conditions: Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM).... Agent: Knobbe Martens Olson & Bear LLP

20080275129 - Methods and pharmaceutical compositions for the treatment of neurological damage: The invention relates to a method of treating neurological damage, preferably spinal chord injury, said treatment comprising the topical administration of guanabenz. The invention also relates to the use of guanabenz for the preparation of a medicament for the treatment of neurological damage, preferably spinal chord injury, wherein said treatment... Agent: Bacon & Thomas, PLLC

20080275130 - Novel derivatives of 3.5-seco-4-norcholestane and use thereof: The invention relates to compounds of formula (I): where X+Y=keto, or X=OH and Y=H, or X+Y=oxime or methyloxime, B=OH and C+D=H, or C+D=C1-C4 linear or branched alkyl, or C=H and D=C1-C4 linear or branched alkyl, or B+C=keto and D=methyl, hydroxyl, or methylamino, or B and C=H and D=methylamino, or B+C=oxime... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080275131 - Compositions of (-)-e-10-oh-nt and methods for their synthesis and use: This present disclosure provides compositions comprising E-10-OH-NT metabolites of AT and NT, methods for their synthesis and methods for their use.... Agent: Dechert LLP

20080275132 - Apparatus and method for making a peroxycarboxylic acid: The present invention relates to apparatus and methods for making a peroxycarboxylic acid. The apparatus includes a reaction catalyst and a guard column for pretreating one or more reagents, which can increase the life, activity, and/or safety of the reaction catalyst. The peroxycarboxylic acid compositions made by the method and... Agent: Merchant & Gould PC

20080275133 - Local administration of retinoids to treat deficiencies in dark adaptation: The present invention relates to improving, at least in part, a deficiency in dark adaptation for an individual. The therapy for dark adaptation includes local administration of a retinoid, such as a Vitamin A or a derivative thereof, such that deleterious side effects seen with systemic administration are avoided.... Agent: Fulbright & Jaworski, LLP

20080275134 - Methods for treatment of retinal degenerative disease: A method is provided for treating a degenerative disease in a vertebrate eye. A method is further provided for preventing photoreceptor degeneration in a vertebrate eye.... Agent: Woodcock Washburn LLP

20080275135 - Resorcinol derivatives and their use for lowering blood pressure: Disclosed are synthetic cannabinoids, namely resorcinol derivatives, which reduce blood pressure without having psychotropic effects. Pharmaceutical compositions for the treatment of high blood pressure related conditions, as well as methods of treating the same utilizing as active agent the compounds of the invention are also disclosed herein. Preferred active compounds... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20080275136 - Use of glycerol for improving cardiac function: The present invention relates to the use of glycerol for the regulation of cardiac metabolism, and notably for reducing myocardial β-oxidation of fatty acids for cardiac cytoprotection.... Agent: Morgan Lewis & Bockius LLP

20080275137 - Lotion composition for personal use: This invention relates to emulsion compositions that can warm on contact with ambient moisture and can be used as lubricants on the skin of a person. They may be formulated in the form of a lotion and maintain stability for a significant period of time.... Agent: Philip S. Johnson Johnson & Johnson

20080275138 - Liquid dispersion polymer compositions, their preparation and their use: Liquid dispersion polymer compositions which comprise microparticles of a hydrophilic, water soluble or swellable polymer with a neutralization level of from about 25% to about 100%, preferably an acrylic-based polymer, dispersed in a suitable non-aqueous carrier fluid and an oil-in-water surfactant, are useful to prepare microparticulate thickening systems to thicken... Agent: Joann Villamizar Ciba Corporation/patent Department

20080275139 - Cyclodextrin-containing polymers and uses thereof: The invention provides a cyclodextrin-containing polymer comprising one or more cyclodextrin residues. The polymer is selected from a peptide, a polypeptide, an oligonucleotide or a polynucleotide or a mixture thereof. The peptide or polypeptide has at least one amino acid residue containing a functional side group and at least one... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080275140 - Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions: The present invention provides a process to make a gelatine hydrolysate, a gelatine hydrolysate, and gelatine compositions including gelatine hydrolysates. More specifically, the invention provides gelatine compositions having a reduced tendency to cross-link and improved dissolution properties.... Agent: Leydig Voit & Mayer, Ltd

20080275141 - Bridged polycyclic compound based compositions for the inhibition and amelioration of disease: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups,... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.